

# CITATION REPORT

List of articles citing

## Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

DOI: 10.1056/nejmoa2023184

New England Journal of Medicine, 2021, 384, 497-511.

**Source:** <https://exaly.com/paper-pdf/77860300/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1691	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. <b>2021</b> , 72, e1130-e1143		14
1690	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. <b>2020</b> , 1, 100146		13
1689	Hydroxychloroquine for COVID-19: Balancing contrasting claims. <b>2020</b> , 82, 25-26		4
1688	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. <b>2020</b> , 9,		6
1687	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. <b>2020</b> , 5,		24
1686	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. <b>2020</b> , 8,		14
1685	SARS-CoV-2 Inhibition by Sulfonated Compounds. <b>2020</b> , 8,		9
1684	Drug treatments for covid-19: living systematic review and network meta-analysis. <b>2020</b> , 370, m2980		331
1683	COVID-19 update: The race to therapeutic development. <b>2020</b> , 53, 100733		33
1682	Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. <b>2020</b> , 8, 1170-1172		69
1681	Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap. <b>2020</b> , 11, 621934		5
1680	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. <b>2020</b> , 7, 596587		7
1679	Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. <b>2020</b> , 41, 4387-4388		6
1678	Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: Molecular Docking Studies and Enzymatic Activity Assay. <b>2020</b> , 8, 623971		24
1677	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. <b>2020</b> , 65,		29
1676	A Large, Simple Trial Leading to Complex Questions. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 576-577	39.2	15
1675	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. <b>2021</b> , 14, 95-103		30

1674	Combining Antivirals and Immunomodulators to Fight COVID-19. <b>2021</b> , 42, 31-44	21
1673	The place for remdesivir in COVID-19 treatment. <b>2021</b> , 21, 20-21	52
1672	A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. <b>2021</b> , 65,	15
1671	Nebulised interferon beta-1a for patients with COVID-19. <b>2021</b> , 9, 122-123	19
1670	How should we use convalescent plasma therapies for the management of COVID-19?. <b>2021</b> , 137, 1573-1581	16
1669	Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review. <b>2021</b> , 61, 581-590	9
1668	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <b>2021</b> , 9, 196-206	219
1667	A retrospective comparison of drugs against COVID-19. <b>2021</b> , 294, 198262	2
1666	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. <b>2021</b> , 23, 886-896	19
1665	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <b>2021</b> , 26, 311-329	0
1664	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <b>2021</b> , 232, 13-36	26
1663	Methodological education in response to the quality of COVID-19 publications. <b>2021</b> , 164, 105381	0
1662	Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics. <b>2021</b> , 538, 40-46	4
1661	Remdesivir: From Ebola to COVID-19. <b>2021</b> , 538, 145-150	18
1660	COVID-19-Directed Medications. <b>2021</b> , 171-179	
1659	Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase.	1
1658	Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic?. <b>2021</b> , 245-255	
1657	COVID19 pandemic is a «pandemic» of antimicrobial therapy. <b>2021</b> , 23, 5-15	2

1656	Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach. <b>2021</b> , 14,	1
1655	Research into policy: lessons from the COVID-19 pandemic. <b>2021</b> , 31, iv3-iv8	0
1654	Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality. <b>2021</b> , 8, ofab003	12
1653	Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys. <b>2021</b> , 9,	96
1652	The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. <b>2021</b> , 12, 488	60
1651	COVID-19: What we've done well and what we could or should have done better-the 4 Ps. <b>2021</b> , 25, 40	7
1650	Update: Drug treatment options for coronavirus disease 2019 (COVID-19). <b>2021</b> , 15, 345-349	2
1649	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. <b>2021</b> , 13, 1930636	7
1648	Editorial: Review of 2020 and what lies ahead in therapeutic interventions. <b>2021</b> , 10,	
1647	[S2k Guideline - Recommendations for Inpatient Therapy of Patients with COVID-19]. <b>2021</b> , 75, 88-112	14
1646	Japanese Rapid/Living recommendations on drug management for COVID-19. <b>2021</b> , 8, e664	6
1645	Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. <b>2021</b> ,	22
1644	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. <b>2021</b> , 25, 441-452	2
1643	Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. <b>2021</b> , 10, e1327	25
1642	Myocarditis in COVID-19 patients: current problems. <b>2021</b> , 16, 1123-1129	29
1641	Genome-scale metabolic modeling reveals SARS-CoV-2-induced host metabolic reprogramming and identifies metabolic antiviral targets. <b>2021</b> ,	1
1640	RGD-binding integrins and TGF- $\beta$ in SARS-CoV-2 infections - novel targets to treat COVID-19 patients?. <b>2021</b> , 10, e1240	12
1639	Ivermectin as a potential treatment for mild to moderate COVID-19 [A double blind randomized placebo-controlled trial.	14

1638	Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial.	4
1637	Remdesivir induces persistent mitochondrial and structural damage in human induced pluripotent stem cell derived cardiomyocytes. <b>2021</b> ,	2
1636	Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. <b>2021</b> , 73, e719-e734	8
1635	structure-based discovery of a SARS-CoV-2 main protease inhibitor. <b>2021</b> , 17, 1555-1564	5
1634	Viral infections in lung transplantation.. <b>2021</b> , 13, 6673-6694	0
1633	The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review. <b>2020</b> , 25, 365-376	3
1632	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. <b>2021</b> , 36, e83	10
1631	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. <b>2021</b> , 10, 2126-2139	1
1630	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. <b>2021</b> , 13,	7
1629	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <b>2021</b> , 71, 411-432	1
1628	A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients. <b>2021</b> , 53, 512-518	1
1627	Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients. <b>2021</b> , 8, ofab001	8
1626	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. <b>2021</b> , 28,	11
1625	Recent biotechnological advances as potential intervention strategies against COVID-19. <b>2021</b> , 11, 41	5
1624	Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines. <b>2021</b> , 53, 151-154	3
1623	[COVID-19 and renal transplantation]. <b>2021</b> , 16, 1-8	0
1622	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. <b>2021</b> , 19, 1661-1671	4
1621	Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries. <b>2021</b> ,	1

1620 Changing profile of COVID-19. **2021**, 9, 2

1619 From SARS and MERS to COVID-19: a review of the quality and responsiveness of clinical management guidelines in outbreak settings. 0

1618 Estado actual de los tratamientos para la COVID-19. **2021**, 28, 40-56 2

1617 Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing. **2021**, 77, 935-937 1

1616 Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality. **2021**, 57, 106254 2

1615 Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. **2021**, 5

1614 Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. **2021**, 71, 342-358 0

1613 Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. **2021**, 49, 401-410 26

1612 ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. **2021**, 28

1611 BCG vaccination in health care providers and the protection against COVID-19. **2021**, 131, 15

1610 Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics. **2021**, 22, 16

1609 Increased COVID-19-related fear and subjective risk perception regarding COVID-19 affects behavior in individuals with internal high-risk diseases. **2021**, 12, 2150132721996898 15

1608 An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. **2021**, 8, 630209 6

1607 Azithromycin, RECOVERY, and the power of large, simple trials. **2021**, 397, 559-560 2

1606 In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2. **2021**, 26, 8

1605 Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. **2021**, 21

1604 Just the facts: updates in COVID-19 therapeutics. **2021**, 23, 283-285

1603 Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. **2021**, 36, 1-14 2

1602	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. <b>2021</b> , 24, 102021	18
1601	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. <b>2021</b> , 371, 926-931	117
1600	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <b>2021</b> , 10, 64	5
1599	Pediatric Coronavirus Disease 2019: Clinical Features and Management. <b>2021</b> , 58, 453-460	3
1598	Remdesivir for COVID-19 in Europe: will it provide value for money?. <b>2021</b> , 9, 127-128	8
1597	COVID-19 illness and autoimmune diseases: recent insights. <b>2021</b> , 70, 407-428	5
1596	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 101, 106272	30
1595	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <b>2021</b> , 89, 780-789	189
1594	Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.	3
1593	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <b>2021</b> , 8, 604087	
1592	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. <b>2021</b> , 9, 74-87	
1591	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <b>2021</b> , 22, 1127-1141	3
1590	Bifurcated monocyte states are predictive of mortality in severe COVID-19. <b>2021</b> ,	4
1589	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <b>2021</b> ,	19
1588	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. <b>2021</b> , 43, 23-32	16
1587	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. <b>2021</b> , 17, e1008686	30
1586	Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study. <b>2021</b> , 58,	5
1585	Inner Workings: Advances in infectious disease treatment promise to expand the pool of donor organs. <b>2021</b> , 118,	2

1584	[Systemic consequences and clinical aspects of SARS-CoV-2 infection]. <b>2021</b> , 42, 155-163	2
1583	Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology. <b>2021</b> , 22,	9
1582	Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity. <b>2021</b> , 9, 2132	1
1581	Pharmacokinetics of Orally Administered GS-441524 in Dogs. <b>2021</b> ,	5
1580	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. <b>2021</b> , 12, 613422	63
1579	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <b>2021</b> , 12, 631139	43
1578	SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. <b>2021</b> , 17, e1009225	74
1577	Adjunctive Nutraceutical Therapies for COVID-19. <b>2021</b> , 22,	16
1576	Group IIA Secreted Phospholipase A Plays a Central Role in the Pathobiology of COVID-19. <b>2021</b> ,	3
1575	Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?. <b>2021</b> , 62, 95-100	5
1574	Gestione del Covid-19 in et^ pediatrica: documento di consenso. <b>2021</b> , 40, 85-101	4
1573	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. <b>2021</b> , 14, 827-833	3
1572	COVID-19: investing in country capacity to bridge science, policy and action. <b>2021</b> , 6,	4
1571	Harnessing biomaterials for therapeutic strategies against COVID-19. <b>2021</b> , 4, 1-10	3
1570	Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. <b>2021</b> ,	39
1569	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. <b>2021</b> , 591, 451-457	131
1568	Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. <b>2021</b> , 3, 1-5	11
1567	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <b>2021</b> , 27, 659-667	52



1566	Convalescent Plasma for the Treatment of Severe COVID-19. <b>2021</b> , 15, 31-38	4
1565	Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.	0
1564	Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir. <b>2021</b> , 27, 49-53	
1563	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. <b>2021</b> , 12, 576448	5
1562	Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. <b>2021</b> , 118,	63
1561	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. <b>2021</b> , 118,	60
1560	Colchicina, perspectivas de un viejo amigo para la reumatolog�a en la COVID-19: una revisi�n exploratoria. <b>2021</b> ,	
1559	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <b>2021</b> , 172, 524-541	38
1558	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. <b>2021</b> , 61, 429-460	13
1557	[Primary care at home in the framework of the COVID-19 pandemic]. <b>2021</b> , 53, 101963	0
1556	Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. <b>2021</b> , 12, 663586	13
1555	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <b>2021</b> , 4, 613-623	3
1554	Impact of remdesivir on 28 day mortality in hospitalized patients with COVID-19: February 2021 Meta-analysis.	1
1553	Remdesivir. 001857872199980	1
1552	A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Health Care Workers in a Tertiary Hospital in Turkey. <b>2021</b> , 47, 948-954	
1551	Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. <b>2021</b> , 4, 898-907	20
1550	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. <b>2021</b> , 75, e14182	2
1549	Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. <b>2021</b> , 6, 107	5

1548	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. 10, 64	0
1547	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. <b>2021</b> , 11, 6725	12
1546	Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan.	2
1545	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. <b>2021</b> , 4, e213071	37
1544	Remdesivir for COVID-19: Why Not Dose Higher?. <b>2021</b> , 65,	5
1543	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. <b>2021</b> , 6, 71	1
1542	COVID-19 and liver disease: mechanistic and clinical perspectives. <b>2021</b> , 18, 348-364	90
1541	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.	
1540	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. <b>2021</b> , 104, 671-676	12
1539	Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner. <b>2021</b> , 8, 653773	1
1538	Safety Consequences of Off-Label Drugs Used for COVID-19. <b>2021</b> , 44, 399-402	0
1537	[Overtreatment in intensive care medicine-recognition, designation, and avoidance : Position paper of the Ethics Section of the DIVI and the Ethics section of the DGIIN]. <b>2021</b> , 116, 281-294	3
1536	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <b>2021</b> , 104, 7-14	9
1535	Current evidence for COVID-19 therapies: a systematic literature review. <b>2021</b> , 30,	11
1534	Internal Medicine Clerkship Amidst COVID-19 Pandemic: A Cross-Sectional Study of the Clinical Learning Experience of Undergraduate Medical Students at Makerere University, Uganda. <b>2021</b> , 12, 253-262	3
1533	Real-life use of remdesivir in hospitalized patients with COVID-19. <b>2021</b> , 34, 136-140	6
1532	SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. <b>2021</b> , 25, e13986	5
1531	Risk factors for mortality in hospitalized patients with COVID-19 from three hospitals in Peru: a retrospective cohort study. <b>2021</b> , 10, 224	6

1530	COVID-19, hydroxychloroquine and the importance of disease progression. <b>2021</b> , 10, 299-311	1
1529	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. <b>2021</b> , 17, 1277-1291	1
1528	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.	5
1527	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. <b>2021</b> , 16, e0247251	14
1526	Withanone from <i>Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model</i> . <b>2021</b> , 15, 1111-1133	25
1525	Twenty articles that critical care clinicians should read about COVID-19. <b>2021</b> , 47, 337-341	3
1524	Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.	
1523	Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 881-882	59.2 4
1522	Amantadine Inhibits SARS-CoV-2 In Vitro. <b>2021</b> , 13,	18
1521	The nucleotide addition cycle of the SARS-CoV-2 polymerase. <b>2021</b> ,	2
1520	Effect of bromhexine in hospitalized patients with COVID-19. <b>2021</b> ,	6
1519	Making science computable: Developing code systems for statistics, study design, and risk of bias. <b>2021</b> , 115, 103685	2
1518	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. <b>2021</b> , 13,	6
1517	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. <b>2021</b> , 22, 1257-1266	4
1516	COVID-19 and the clinical course of rheumatic manifestations. <b>2021</b> , 40, 2611-2619	29
1515	SARS-CoV-2/COVID-19 Aktualisierte Empfehlungen zu Diagnostik und Therapie. <b>2021</b> , 29, 80-89	1
1514	How to Treat COVID-19 Patients at Home in the Italian Context: An Expert Opinion. <b>2021</b> , 13, 251-258	4
1513	Toxicity of herbal medications suggested as treatment for COVID-19: A narrative review. <b>2021</b> , 2, e12411	3

1512	Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs.	2
1511	Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry.	1
1510	The Essential Role of Data and Safety Monitoring Boards (DSMBs) in Ensuring the Ethics of Global Vaccine Trials to Address Coronavirus Disease 2019 (COVID-19O). <b>2021</b> , 73, 2126-2130	0
1509	A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors.	
1508	Remdesivir: An Antiviral Still Seeking a Raison d'Être. <b>2021</b> , 73, 1857-1859	
1507	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. <b>2021</b> , 54, 557-570.e5	84
1506	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. <b>2021</b> , 53, 435-444	62
1505	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <b>2021</b> , 57,	76
1504	In Reply - Does Hypoxia Itself Beget Worsening Hypoxemia in COVID-19?. <b>2021</b> , 96, 825-827	
1503	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <b>2021</b> , 22, 224	4
1502	Experimental therapies under investigation for COVID-19. <b>2021</b> , 11, 187-193	2
1501	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. <b>2021</b> , 26, 220-239	4
1500	Nowcasting epidemics of novel pathogens: lessons from COVID-19. <b>2021</b> , 27, 388-395	11
1499	The RNA sensor MDA5 detects SARS-CoV-2 infection.	1
1498	The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia. <b>2021</b> , 9,	4
1497	Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. <b>2021</b> , 17, e1008752	21
1496	Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir. <b>2021</b> , 1-3	4
1495	Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?". <b>2021</b> , 65,	2

1494	What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. <b>2021</b> , 13, 175-184	5
1493	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. <b>2021</b> , 246, 1533-1540	1
1492	COVID-19 research in critical care: the good, the bad, and the ugly. <b>2021</b> , 47, 470-472	3
1491	IFNL4 genetic variant can predispose to COVID-19.	3
1490	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <b>2021</b> , 17, 24	7
1489	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. <b>2021</b> , 12, 632677	28
1488	The first 12 months of COVID-19: a timeline of immunological insights. <b>2021</b> , 21, 245-256	140
1487	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. <b>2021</b> , 13, 259-284	12
1486	SARS-CoV-2 proteins bind heme and hemoglobin.	2
1485	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. <b>2021</b> , 76, 1865-1873	3
1484	Autoantibodies against Progranulin and IL-1 receptor antagonist in critically ill COVID-19.	1
1483	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. <b>2021</b> , 100, e25532	
1482	Highlights from a year in a pandemic. <b>2021</b> , 218,	3
1481	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response. <b>2021</b> , 76, 1651-1652	
1480	Management and Prevention of COVID-19 in Pregnancy and Pandemic Obstetric Care: A Review of Current Practices. <b>2021</b> , 9,	9
1479	Predictive association of C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients. <b>2021</b> , 22, 375-381	1
1478	. <b>2021</b> , 193, E495-E496	
1477	Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. <b>2021</b> , 28, e299-e318	52

1476	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. <b>2021</b> , 27, 668-676	19
1475	Compassionate Use of Remdesivir in Children With Severe COVID-19. <b>2021</b> , 147,	23
1474	Applications and challenges of AI-based algorithms in the COVID-19 pandemic. <b>2021</b> , 7, 387-398	6
1473	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <b>2021</b> , 19, 1331-1339	2
1472	An update to monoclonal antibody as therapeutic option against COVID-19. <b>2021</b> , 3, 87-91	54
1471	Smarter cures to combat COVID-19 and future pathogens: a review. <b>2021</b> , 19, 1-13	12
1470	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. <b>2021</b> , 17, 371-387	31
1469	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. <b>2021</b> , 4, e216468	50
1468	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. <b>2021</b> , 11, 9023	21
1467	Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching. <b>2021</b> , 105, 525-531	8
1466	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. <b>2021</b> , 12, 576093	10
1465	COVID-19: Antiviral Tedavi.	
1464	Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy. <b>2021</b> , 2021, 6648199	12
1463	Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19". <b>2021</b> , 57, 65-66	1
1462	Quest for a Cure: Potential Small-Molecule Treatments for COVID-19, Part 2. <b>2021</b> , 25, 1089-1111	6
1461	The race for antiviral drugs to beat COVID - and the next pandemic. <b>2021</b> , 592, 340-343	39
1460	S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie □ AWMF-Register Nr. 021-031 Stand: 07.01.21. <b>2021</b> , 59, 345-359	4
1459	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. <b>2021</b> , 9, 763-772	143

1458	Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients.	2
1457	Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. <b>2021</b> , 193, E612-E615	8
1456	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <b>2021</b> , 77, 1903-1921	84
1455	Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. <b>2021</b> ,	18
1454	SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population. <b>2021</b> , 10,	3
1453	From bedside to bench: regulation of host factors in SARS-CoV-2 infection. <b>2021</b> , 53, 483-494	1
1452	Evaluating alternative hypotheses to explain the downward trend in the indices of the COVID-19 pandemic death rate. <b>2021</b> , 9, e11150	1
1451	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. <b>2021</b> , 12, 621676	0
1450	SARS-CoV-2/COVID-19 İktualisierte Empfehlungen zu Diagnostik und Therapie. <b>2021</b> , 56, 277-287	
1449	Early experience with COVID-19 patients in a private tertiary hospital in the Philippines: Implications on surge capacity, healthcare systems response, and clinical care. <b>2021</b> , 10, 100695	2
1448	COVID-19 HASTALARINDA KORTKÖSTERÖD TEDAVSİNE ZAMAN VE NASIL?.	
1447	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. <b>2021</b> , 13,	12
1446	RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. <b>2021</b> , 103, 106330	3
1445	Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. <b>2021</b> , 9, 576-586	
1444	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. 147775092110114	0
1443	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <b>2021</b> , 82, 58-66	25
1442	Cytokine Storm. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, e59	59.2 8
1441	Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry, Inflammation and New Therapeutics.	1

1440	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <b>2021</b> , 218,	79
1439	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. <b>2021</b> , 13,	6
1438	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. <b>2021</b> , 9, E693-E702	7
1437	The time to offer treatments for COVID-19. <b>2021</b> , 30, 505-518	9
1436	Interferon $\beta$ 1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease. <b>2021</b> , 93, 4102-4107	3
1435	Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity. <b>2021</b> , 4, e217746	13
1434	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. <b>2021</b> , 14,	9
1433	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry. <b>2021</b> , 43, 1877-1897	0
1432	Hearing Loss, Tinnitus, and Dizziness in COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 1-12	18
1431	Letter from Malaysia. <b>2021</b> , 26, 624-626	
1430	Use of Remdesivir in Myasthenia gravis and COVID-19. <b>2021</b> , 41, 546-550	2
1429	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. <b>2021</b> , 18,	13
1428	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. <b>2021</b> ,	9
1427	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. <b>2021</b> , 19, 425-441	47
1426	The immune response to the novel coronavirus infection. <b>2021</b> , 12, 33-40	1
1425	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <b>2021</b> , 8, ofab278	8
1424	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <b>2021</b> , 8, 681-691	2
1423	INSIGHTS INTO CORONA/CORONAVIRUS DISEASE 2019 PANDEMIC [OPINION VERSUS EVIDENCE. 13-15	0



1422	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. <b>2021</b> , 10,	1
1421	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ 1a and hydroxychloroquine in hospitalized patients with COVID-19. <b>2021</b> , 27, 1826-1837	27
1420	The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy. <b>2021</b> , 53, 1194-1201	5
1419	IL-6 blockade for COVID-19: a global scientific call to arms. <b>2021</b> , 9, 438-440	15
1418	COVID-19: breaking down a global health crisis. <b>2021</b> , 20, 35	43
1417	Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids. <b>2021</b> , 43, 871-885	3
1416	Exploring protein hotspots by optimized fragment pharmacophores. <b>2021</b> , 12, 3201	9
1415	Antiviral Efficacy of Pralatrexate against SARS-CoV-2. <b>2021</b> , 29, 268-272	1
1414	Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU?-a viewpoint. <b>2021</b> , 25, 178	2
1413	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <b>2021</b> ,	2
1412	Management of severe covid-19: progress and promise. <b>2021</b> , 373, n1147	4
1411	COVID-19 and syndemic challenges in 'Battling the Big Three': HIV, TB and malaria. <b>2021</b> , 106, 29-32	8
1410	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. <b>2021</b> , 9,	4
1409	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. <b>2021</b> , 77, 1513-1521	2
1408	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <b>2021</b> , 12, 3189	76
1407	Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. <b>2021</b> , 4, e218828	43
1406	Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome. <b>2021</b> , 7, e27609	1
1405	Current advances in pharmacological treatments for patients with COVID-19. <b>2021</b> , 64, 375-385	

1404	Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. <b>2021</b> , 19, 198	7
1403	Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. <b>2021</b> , 36, 451-461	5
1402	How COVID-19 has fundamentally changed clinical research in global health. <b>2021</b> , 9, e711-e720	20
1401	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness.	
1400	No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study. <b>2021</b> , 100, e26023	2
1399	Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PROACT-COVID study in The Netherlands. <b>2021</b> , 9, 813	1
1398	Keine Wirksamkeit antiviraler Substanzen bei COVID-19 Interimsergebnisse des WHO-Solidarity-Trials. <b>2021</b> , 56, 310-310	
1397	Virologische Erkrankungen auf der Intensivstation. <b>2021</b> , 17, 155-176	
1396	Guidelines for Reopening a Nation in a SARS-CoV-2 Pandemic: A Path Forward. <b>2021</b> , 57,	2
1395	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <b>2021</b> ,	1
1394	The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. <b>2021</b> , 9,	3
1393	Antiviral treatment selection for SARS-CoV-2 pneumonia. <b>2021</b> , 15, 985-992	1
1392	What we know and dont know on SARS-CoV-2 and COVID-19. <b>2021</b> , 21, e8198	
1391	COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. <b>2021</b> , 18, 28	10
1390	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <b>2021</b> , 10, 1323-1330	9
1389	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. <b>2021</b> , 11, 9609	18
1388	Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies. <b>2021</b> , 110, 321-333	4
1387	The COVID-19 Menace. <b>2021</b> , 5, 2100004	2

1386	Clinical features and prognostic factors of intensive and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia. <b>2021</b> , 26, 47	12
1385	Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States. <b>2021</b> , 24, 632-640	5
1384	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. <b>2021</b> , 378, 166-172	6
1383	Overview of SARS-CoV-2 infection in adults living with HIV. <b>2021</b> , 8, e294-e305	46
1382	Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. <b>2021</b> , 14,	11
1381	COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update. <b>2021</b> , 53, 1227-1236	5
1380	Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. <b>2021</b> , 12, 657363	6
1379	Genetics of COVID-19. <b>2021</b> , 12, 41-52	1
1378	Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. <b>2021</b> , 26, 41	14
1377	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses.	2
1376	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. <b>2021</b> , 35, 100849	60
1375	Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. <b>2021</b> , 11, 10641	33
1374	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <b>2021</b> , 238, 569-578	0
1373	Differential interferon- $\beta$ subtype immune signatures suppress SARS-CoV-2 infection.	2
1372	On the road to Recovery-the world's biggest covid-19 treatment trial. <b>2021</b> , 373, n1299	3
1371	Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. <b>2021</b> , 17, 2841-2850	5
1370	In silico and in vitro Demonstration of Homoharrintonine's Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model.	4
1369	Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. <b>2021</b> , 21, e342-e347	10

1368	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <b>2021</b> , 14, 601-621	29
1367	Current Strategies of Antiviral Drug Discovery for COVID-19. <b>2021</b> , 8, 671263	24
1366	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. <b>2021</b> , 7, 1519-1534	20
1365	COVID-19: The therapeutic landscape. <b>2021</b> , 2, 493-497	7
1364	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. <b>2021</b> , 9, 2951-2968	4
1363	Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study. <b>2021</b> , 1, 2-12	7
1362	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <b>2021</b> , 73, e1397-e1401	17
1361	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <b>2021</b> , 106, 265-268	0
1360	AIDS and COVID: A tale of two pandemics and the role of statisticians. <b>2021</b> , 40, 2499-2510	7
1359	Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study. <b>2021</b> , 18, 101	4
1358	Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.	4
1357	Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. <b>2021</b> , 53, 691-699	8
1356	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 14, 1101-1112	4
1355	Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation. <b>2021</b> , 23, e13629	14
1354	Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic. <b>2021</b> , 106, 43-51	5
1353	A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19.	11
1352	Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. <b>2021</b> , 49, 37	55
1351	Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection. <b>2021</b> , 7, 21	9

1350	COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE). <b>2021</b> , 108, 490-500	1
1349	Drug combination therapy for emerging viral diseases. <b>2021</b> , 26, 2367-2376	11
1348	International COVID-19 trial to restart with focus on immune responses. <b>2021</b> ,	7
1347	Monitoring clinical trials in infectious diseases.. <b>2021</b> , 2, 29-32	
1346	Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells.	1
1345	Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study. <b>2021</b> , 18, 102	4
1344	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. <b>2021</b> , 373, n1038	19
1343	A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. <b>2021</b> , 106, 71-77	13
1342	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <b>2021</b> , 10,	5
1341	Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19.	1
1340	Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. <b>2021</b> , 14,	1
1339	Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre. <b>2021</b> , 2021, e202111	1
1338	Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis. <b>2021</b> , 25, 515-522	1
1337	The role of antirheumatics in patients with COVID-19. <b>2021</b> , 3, e447-e459	19
1336	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <b>2021</b> , 117, 2148-2160	8
1335	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <b>2021</b> , 115, 456-466	5
1334	Clinical Management of COVID-19 Patients - An Update. <b>2022</b> , 52, 4-10	7
1333	Drug Repurposing of potential drug targets for treatment of COVID-19.	

1332	Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial).	0
1331	In Silico and In Vitro Analyses Validate Human MicroRNAs Targeting the SARS-CoV-2 3'-UTR. <b>2021</b> , 22,	3
1330	Future developments in the prevention, diagnosis and treatment of COVID-19. <b>2021</b> , 73, 56-80	2
1329	Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain. <b>2021</b> , 38, 4057-4069	1
1328	Remdesivir to treat COVID-19: can dosing be optimized?.	
1327	Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. <b>2021</b> , 12, 680188	0
1326	Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. <b>2021</b> , 4, 1408-1421	14
1325	COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. <b>2021</b> , 16, e0252591	9
1324	A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2. <b>2021</b> , 12, 685308	5
1323	COVID-19 chemoprevention. <b>2021</b> , 107, 31-33	
1322	Factors associated with COVID-19 susceptibility and severity in patients with multiple sclerosis: A systematic review.	2
1321	Use of hiPSC-derived cardiomyocytes to rule out proarrhythmic effects of drugs: the case of hydroxychloroquine in COVID-19.	
1320	Disputes over the production and dissemination of misinformation in the time of COVID-19. <b>2021</b> , 182, 106380	3
1319	Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12. <b>2021</b> ,	
1318	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <b>2021</b> , 18, 261-270	2
1317	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <b>2021</b> , 9,	2
1316	Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. <b>2021</b> , 224, S1-S21	12
1315	Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. <b>2021</b> , 39, 4108-4116	31

1314	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. <b>2021</b> , 23, e31400	2
1313	COVID-19: Sleep, Circadian Rhythms and Immunity - Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. <b>2021</b> , 15, 674204	5
1312	Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial.	10
1311	An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World's Population. <b>2021</b> , 9,	1
1310	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. <b>2021</b> , 12, 650465	10
1309	Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. <b>2021</b> , 215, 56-58.e1	1
1308	SARS-CoV-2/COVID-19 Aktualisierte Empfehlungen zu Diagnostik und Therapie. <b>2021</b> , 15, 205-215	
1307	[Antiviral drugs in emergencies]. <b>2021</b> , 24, 1-8	
1306	On-Site Detection of SARS-CoV-2 Antigen by Deep Learning-Based Surface-Enhanced Raman Spectroscopy and Its Biochemical Foundations. <b>2021</b> , 93, 9174-9182	14
1305	Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?. <b>2021</b> , 8, ofab318	3
1304	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <b>2021</b> , 8, 639970	9
1303	Perspectives on Antiviral Drugs Development in the Treatment of COVID-19. <b>2021</b> , 4, 44-59	
1302	Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. <b>2021</b> , 11, 11974	9
1301	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. <b>2021</b> , 76, 2415-2418	4
1300	Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study. <b>2021</b> , 53, 820-829	1
1299	Neuromodulatory effects of SARS-CoV2 infection: Possible therapeutic targets. <b>2021</b> , 25, 509-519	
1298	Keine Wirksamkeit antiviraler Substanzen bei COVID-19 Interimsergebnisse des WHO Solidarity Trials. <b>2021</b> , 146, 783-784	
1297	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <b>2021</b> , 558, 1-12	9

1296	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). <b>2021</b> , 1	0
1295	Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19. <b>2021</b> , 2, 229-245	2
1294	Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo.	3
1293	Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology.	1
1292	Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. <b>2021</b> , 16, e0252984	9
1291	Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <b>2021</b> , 73, 2031-2036	20
1290	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <b>2021</b> , 10, 64	4
1289	Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness.	
1288	Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,	3
1287	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. <b>2021</b> , 10,	2
1286	monotherapy-with-lopinavir-ritonavir-or-in-combination-with-interferon-beta-1b-in-patients-with-non-severe-covid-19-di <b>2021</b> , 7, 11-15	
1285	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <b>2021</b> , 10,	2
1284	[SARS-CoV-2 infection: Available data on 15th April 2021]. <b>2021</b> , 38, 616-625	
1283	Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. <b>2021</b> , 11, e048416	14
1282	Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis.	2
1281	Non-traditional Use of HEOR To Identify Host Response Treatments During a Pandemic. <b>2021</b> , 8, 125-126	
1280	Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. <b>2021</b> , 4, 2100059	4
1279	Update in COVID-19 2020. <b>2021</b> , 203, 1462-1471	5



1278	Therapeutic Agents Rounding Up the Immunopathology of COVID-19. <b>2021</b> , 17, 657-668	1
1277	SARS-CoV-2 and hypertension. <b>2021</b> , 9, e14800	4
1276	Non-traditional Use of HEOR To Identify Host Response Treatments During a Pandemic.. <b>2021</b> , 8, 125-126	
1275	Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. <b>2021</b> , 54, 767-775	9
1274	Cytolytic syndrome associated with the treatment for COVID-19. <b>2021</b> , 140-146	
1273	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. <b>2021</b> , 16, e0252388	2
1272	Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review. <b>2021</b> , 13,	2
1271	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint).	
1270	Roles and Interplay of SARS-CoV-2 Serology With Clinical Stages of Disease in COVID-19. <b>2021</b> , 13, e15953	
1269	Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. <b>2021</b> , 16, e0252306	4
1268	. <b>2021</b> , 193, E987-E991	
1267	Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. <b>2021</b> , 82, 276-316	7
1266	Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls-A Prospective Cohort Study. <b>2021</b> , 10,	3
1265	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <b>2021</b> , 11, 12414	6
1264	Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. <b>2021</b> , 15, 1181-1187	
1263	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <b>2021</b> , 1-19	4
1262	Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. <b>2021</b> , 7, 2337-2351	8
1261	A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. <b>2021</b> , 27, 917.e1-917.e4	8

1260	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN- $\gamma$ <b>2021</b> , 41, 1425-1442	13
1259	Advancing precision medicine for acute respiratory distress syndrome. <b>2021</b> ,	10
1258	SARS-CoV-2 Antiviral Therapy. <b>2021</b> , e0010921	12
1257	The effect of the outbreak of COVID-19 on respiratory physicians and healthcare in Japan: Serial nationwide surveys by the Japanese Respiratory Society. <b>2021</b> , 59, 792-798	0
1256	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <b>2021</b> , 14, 3419-3428	4
1255	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease. <b>2021</b> , 478, 2445-2464	11
1254	A retrospective multi-center experience of renal transplants from India during COVID-19 pandemic. <b>2021</b> , 35, e14423	5
1253	Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. <b>2021</b> , 11,	4
1252	The Anti-Viral Applications of Marine Resources for COVID-19 Treatment: An Overview. <b>2021</b> , 19,	6
1251	Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia. <b>2021</b> , 11, 03087	0
1250	Integrative management of critical case of Covid 19 with and Modern medicine: A case report. <b>2021</b> , 13, 100496-100496	
1249	Impact of second wave of Covid-19 on tuberculosis control. <b>2021</b> , 68, 311-312	0
1248	[Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review]. <b>2021</b> , 25, 494-501	
1247	[Update 2021: COVID-19 from the perspective of cardiology]. <b>2021</b> , 146, 911-914	
1246	Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. <b>2021</b> ,	8
1245	Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?. <b>2021</b> , 13,	0
1244	In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. <b>2021</b> , 11, 14571	18
1243	No shortcuts to SARS-CoV-2 antivirals. <b>2021</b> , 373, 488-489	6

1242	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. <b>2021</b> , 139, 111642	19
1241	Variation in therapeutic strategies for the management of severe COVID-19 in India: A nationwide cross-sectional survey. <b>2021</b> , 75, e14574	0
1240	Impact of COVID-19 on cancer care in India: a cohort study. <b>2021</b> , 22, 970-976	39
1239	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <b>2021</b> , 33, 419-430	18
1238	A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening. <b>2021</b> ,	
1237	Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. <b>2021</b> , 102,	2
1236	Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation. <b>2021</b> , 17, 84	1
1235	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. <b>2021</b> , 96, 107636	6
1234	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase. <b>2021</b> , 478, 2425-2443	9
1233	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. <b>2021</b> , 21, e801-e809	3
1232	Review: The Nose as a Route for Therapy. Part 2 Immunotherapy.. <b>2021</b> , 2, 668781	1
1231	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <b>2021</b> , 29, 1331-1346	4
1230	Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2. <b>2021</b> , 65, e0049121	5
1229	The global governance of pandemics. <b>2021</b> , 43, 1540-1553	1
1228	Update Alert: Remdesivir for Adults With COVID-19. <b>2021</b> , 174, W65	5
1227	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review. <b>2021</b> , 66, 1603975	0
1226	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <b>2021</b> , 10,	9
1225	High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19. <b>2021</b> , 12, 704767	4

1224	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <b>2021</b> ,	12
1223	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <b>2021</b> , 47, 867-886	20
1222	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <b>2021</b> , 505, 108326	19
1221	N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence. <b>2021</b> , 14, 2993-3013	7
1220	Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings. <b>2021</b> , 16, e0255093	3
1219	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <b>2021</b> , 108, 370-376	3
1218	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. <b>2021</b> , e2276	2
1217	Opportunities for the use of routinely collected data for the generation of large randomized evidence in Colombia. 6, 182	
1216	Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19.	1
1215	COVID-19 pneumonia: What APRNs should know. <b>2021</b> , 46, 22-28	
1214	Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies.	2
1213	Hypotheses and facts for genetic factors related to severe COVID-19. <b>2021</b> , 10, 137-155	1
1212	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. <b>2021</b> , 14,	3
1211	In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease. <b>2021</b> , 16, 2339-2344	2
1210	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <b>2021</b> , 10, 1837-1885	10
1209	How trustworthy guidelines can impact outcomes. <b>2021</b> , 27, 544-550	0
1208	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <b>2021</b> , 2021, 1-22	0
1207	Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience.	

1206 A Highly Potent SARS-CoV-2 Blocking Lectin Protein.

1205 SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: an in-silico proof-of-principle of proteomics-based drug repurposing.

1204 Pathogenesis of the initial stages of severe COVID-19. **2021**, 12, 83-102

2

1203 Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). **2021**, 11,

1

1202 Ivermectin as a multifaceted drug in COVID-19: Current insights. **2021**, 77, S254-S256

1

1201 The Second Wave of COVID-19: Clinical Pharmacy Services During a Field Hospital Operation. 001857872110328

1200 Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19. **2021**, 16, e0254374

2

1199 Contemporary narrative review of treatment options for COVID-19. **2021**, 26, 745-767

6

1198 Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19.

1

1197 The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. **2021**, 11, 100755

13

1196 The predictors of high titer of -SARS-CoV-2 antibody of convalescent plasma donors. **2021**, 11, 100763

2

1195 Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure. **2021**, 42, 3783-3785

1

1194 Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. **2021**, 10, 2291-2307

7

1193 Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro. **2021**, 11, 14295

7

1192 What we learned in the past year in managing our COVID-19 patients in intensive care units?. **2021**, 10, 81-101

1

1191 Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality. **2021**, 1-16

3

1190 COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?. **2021**, 14,

0

1189 Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. **2021**, 18, 154

4

1188	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). <b>2021</b> , 1	6
1187	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. <b>2021</b> , 10, 1907-1931	12
1186	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.	1
1185	Characteristics, therapeutic modalities and outcomes of COVID-19 ventilated patients in a tertiary care hospital in counter-insurgency zone: Our experience. <b>2021</b> , 77, S345-S352	
1184	Epidemiology and Clinical Characteristics in Individuals with Confirmed SARS-CoV-2 Infection During the Early COVID-19 Pandemic in Saudi Arabia.	
1183	Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection. <b>2021</b> , 8, ofab358	22
1182	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <b>2021</b> , 11,	44
1181	The RNA sensor MDA5 detects SARS-CoV-2 infection. <b>2021</b> , 11, 13638	27
1180	Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. <b>2021</b> ,	3
1179	Commentary: Why Haven't We Found an Effective Treatment for COVID-19?. <b>2021</b> , 12, 714175	1
1178	Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir.	
1177	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease. <b>2021</b> , 478, 2465-2479	11
1176	Mécanismes possiblement impliqués dans les effets antiviraux de la chloroquine et de l'hydroxychloroquine [Quelle rôle pour le traitement de la COVID-19 ?]. <b>2021</b> , 33, 237-237	
1175	From severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) to coronavirus disease 2019 (COVID-19): a systematic review of the quality and responsiveness of clinical management guidelines in outbreak settings. 6, 170	0
1174	Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. <b>2021</b> , 16, e0254453	13
1173	Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19. <b>2021</b> , 11, e046738	4
1172	[Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination]. <b>2021</b> , 36, 451-461	1
1171	Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. <b>2021</b> , 118,	18

1170	The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas. <b>2021</b> , 13, e16351	
1169	Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis. <b>2021</b> , 57, 102331	14
1168	Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. <b>2021</b> , 4, e2114741	28
1167	Evaluation of toxicity and effectiveness of the anti-malaria preparation mefloquine with respect to SARS-CoV-2 in experiments on animals. <b>2021</b> , 44-49	0
1166	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies-a narrative review. <b>2021</b> , 14, 863-875	15
1165	Heparin for Moderately Ill Patients with Covid-19. <b>2021</b> ,	8
1164	Effectiveness of favipiravir in COVID-19: a live systematic review. <b>2021</b> , 40, 2575-2583	12
1163	Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. <b>2021</b> , 16, e0255608	7
1162	Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19. <b>2021</b> , 4,	2
1161	An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). <b>2021</b> , 1-10	7
1160	Extracorporeal Blood Purification Is Appropriate in Critically Ill Patients with COVID-19 and Multiorgan Failure: PRO.. <b>2022</b> , 3, 416-418	2
1159	Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. <b>2021</b> , 22,	3
1158	A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. <b>2021</b> , 1	2
1157	India and management of COVID-19: A case study on published guidelines. <b>2021</b> , 15, 171-179	
1156	Kidney implications of SARS-CoV2 infection in children. <b>2021</b> , 1	2
1155	Comparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis. <b>2021</b> , 160, 106-111	0
1154	Remdesivir for the treatment of COVID-19. <b>2021</b> , 8, CD014962	22
1153	Individual health behaviours to combat the COVID-19 pandemic: lessons from HIV socio-behavioural science. <b>2021</b> , 24, e25771	2

1152	Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. <b>2021</b> , 93, 6750-6759	7
1151	SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. <b>2021</b> , 23, 129	3
1150	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. <b>2021</b> , 1-12	3
1149	Pathogenesis and treatment of cytokine storm in COVID-19. <b>2021</b> , 45, 372-389	3
1148	Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. <b>2021</b> ,	7
1147	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. <b>2021</b> , 11, 164	2
1146	Significant Publications on Infectious Diseases Pharmacotherapy in 2020. <b>2021</b> , 8971900211040438	1
1145	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. <b>2021</b> ,	1
1144	Remdesivir and Mortality in Patients with COVID-19. <b>2021</b> ,	5
1143	Effect of Remdesivir on COVID-19 PCR Positivity and Cycle Threshold in Kidney Transplant Recipients. <b>2021</b> , 2, 291-293	1
1142	Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <b>2021</b> ,	10
1141	Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data. <b>2021</b> , 20, 1559-1564	7
1140	Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. <b>2021</b> ,	3
1139	Cytokine adsorption and ECMO in patients with COVID-19. <b>2021</b> , 9, e71	2
1138	Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. <b>2021</b> , 17, e1009427	12
1137	Immunocompromised patients with SARS-CoV-2 infection in intensive care units, outcome and mortality. <b>2021</b> , 6, 021-025	
1136	Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. <b>2021</b> ,	3
1135	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. <b>2021</b> , 13,	10



1134	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <b>2021</b> , 93, 6737-6749	4
1133	Antirheumatic drugs and COVID-19: frustrations and hopes. <b>2021</b> , 134-139	
1132	SARS-CoV-2 infectivity correlates with high viral loads and detection of viral antigen and is terminated by seroconversion. <b>2021</b> ,	6
1131	Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. <b>2021</b> , 28, 740-746	108
1130	Remdesivir for the treatment of Covid-19: the value of biochemical studies. <b>2021</b> , 49, 81-85	6
1129	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <b>2021</b> , 6, 317	17
1128	The nucleotide addition cycle of the SARS-CoV-2 polymerase. <b>2021</b> , 36, 109650	6
1127	Inflammasome activation at the crux of severe COVID-19. <b>2021</b> , 21, 694-703	50
1126	Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis. <b>2021</b> , 1-12	3
1125	Exploiting an early immunological window of opportunity in COVID-19. <b>2021</b> , 9, 811-812	0
1124	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications.	1
1123	Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. <b>2022</b> , 94, 384-387	2
1122	Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review.	
1121	Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. <b>2021</b> , 3, e0488	0
1120	Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and Experimental Validation of Computationally Screened Inhibitors. <b>2021</b> , 61, 4082-4096	11
1119	IMMUNOLOGICAL INSIGHTS INTO THE THERAPEUTIC ROLES OF CD24Fc AGAINST SEVERE COVID-19. <b>2021</b> ,	1
1118	SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites. <b>2021</b> , 22,	11
1117	Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences. <b>2021</b> , 27, 1724-1726	4

1116	Outcomes of extracorporeal membrane oxygenation in influenza versus COVID-19 during the first wave of COVID-19. <b>2021</b> , 36, 3740-3746	5
1115	A review of remdesivir for COVID-19 in pregnancy and lactation. <b>2021</b> ,	5
1114	Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2. <b>2021</b> , 560, 110-115	2
1113	Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. <b>2021</b> , 4,	2
1112	The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. <b>2021</b> , 1	6
1111	Medicinal plants as immune booster in the palliative management of viral diseases: A perspective on coronavirus.	2
1110	Evidence-based public policy making for medicines across countries: findings and implications for the future. <b>2021</b> , 10, 1019-1052	7
1109	What is the role of remdesivir in patients with COVID-19?. <b>2021</b> , 27, 487-492	5
1108	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. <b>2021</b> , 8, ofab391	1
1107	A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases.	
1106	The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids. <b>2021</b> , 76, 2690-2696	5
1105	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <b>2021</b> , 13,	2
1104	Characterization of ACE Inhibitors and ATR Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. <b>2021</b> , 11,	2
1103	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <b>2021</b> , 7, 65	7
1102	SARS-CoV-2 suppresses IFN $\gamma$ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. <b>2021</b> , 17, e1009800	13
1101	Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial.	2
1100	Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment. <b>2021</b> , 61, 4745-4757	3
1099	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. <b>2021</b> ,	15

1098	Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids. <b>2021</b> , 23, 822-833	7
1097	Clinical Research: From Case Reports to International Multicenter Clinical Trials. <b>2021</b> , 49, 1866-1882	3
1096	Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. <b>2021</b> , 20, 1299-1307	2
1095	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <b>2021</b> , 11, 7457	6
1094	Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial.	1
1093	Building global health research capacity to address research imperatives following the COVID-19 pandemic. <b>2021</b> , 18, e1003753	1
1092	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <b>2021</b> , 49, 183-193	9
1091	Immunomodulatorische Therapien bei Multipler Sklerose in der Pandemie. <b>2021</b> , 23, 38-47	0
1090	Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020. <b>2021</b> , 44, 987-998	2
1089	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <b>2021</b> , 10,	4
1088	Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program. <b>2021</b> , 10, 2511-2524	2
1087	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <b>2021</b> ,	5
1086	A Comparative Study on Virology, Epidemiology, and Clinical Features of SARS and COVID-19. <b>2021</b> , 1-8	
1085	Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. <b>2021</b> , 22, 2455-2474	0
1084	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <b>2021</b> , 10,	2
1083	Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19. <b>2021</b> , 41, e0018521	7
1082	Lectin from (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <b>2021</b> , 22,	3
1081	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <b>2021</b> ,	66

1080	Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray. <b>2021</b> ,	1
1079	Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. <b>2021</b> , 9,	4
1078	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <b>2021</b> , 6, eabd0205	5
1077	Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. <b>2021</b> , 65, e0111721	7
1076	Management of COVID-19-Related Severe Acute Respiratory Distress Syndrome in a Patient With Active Human Immunodeficiency Virus Infection. <b>2021</b> , 13, e18045	
1075	Reconsidering 'minimal risk' to expand the repertoire of trials with waiver of informed consent for research. <b>2021</b> , 11, e048534	0
1074	The role of type I interferon in the treatment of COVID-19. <b>2022</b> , 94, 63-81	11
1073	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. <b>2021</b> , 6, 2305-2315	7
1072	The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors. <b>2021</b> , 12, 746602	0
1071	Nafamostat-Interferon- $\alpha$ Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. <b>2021</b> , 13,	4
1070	Fractal-fractional order mathematical vaccine model of COVID-19 under non-singular kernel. <b>2021</b> , 150, 111150	6
1069	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. <b>2021</b> ,	8
1068	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. <b>2021</b> , 17, e1009929	29
1067	Current status of therapeutic alternatives for COVID-19: A narrative review.. <b>2021</b> , 29, 312-327	2
1066	Effect of mortality from COVID-19 on inpatient outcomes. <b>2022</b> , 94, 318-326	3
1065	Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. <b>2021</b> , 17, e1009898	7
1064	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). <b>2021</b> ,	16
1063	Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. <b>2021</b> , 13,	5

1062	Remdesivir, on the road to DisCoVeRy. <b>2021</b> ,	5
1061	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. <b>2021</b> , 2021, 5942366	2
1060	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. <b>2021</b> ,	2
1059	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. <b>2021</b> , 112, 300-317	4
1058	Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.	
1057	Protons to Patients: targeting endosomal Na <sup>+</sup> /H exchangers against COVID-19 and other viral diseases. <b>2021</b> , 288, 5071-5088	0
1056	A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019. <b>2021</b> , 11,	2
1055	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. <b>2021</b> , 12, 5498	15
1054	Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. <b>2021</b> , 11, 17810	6
1053	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <b>2021</b> , 16, e0257376	2
1052	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. <b>2021</b> , 9, 758347	1
1051	Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies. <b>2021</b> , 13,	2
1050	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. <b>2021</b> , 22, 1428-1439	22
1049	Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells. <b>2021</b> ,	4
1048	An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. <b>2021</b> , 367, 104398	1
1047	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <b>2021</b> , 23, 6364-6376	4
1046	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <b>2021</b> , 105, 584-595	3
1045	Combination therapies for COVID-19: An overview of the clinical trials landscape. <b>2021</b> ,	4

1044	COVID-19 Critical Illness: A Data-Driven Review. <b>2021</b> ,	3
1043	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. <b>2021</b> , 16, 1105-1133	3
1042	Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. <b>2021</b> , 16, e0257784	6
1041	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <b>2021</b> , 76, 3296-3302	4
1040	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 9, 729559	7
1039	Intravenous Immunoglobulin (IVIg) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted.	
1038	Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. <b>2021</b> , 118,	6
1037	Experimental and clinical evaluation of mefloquine effectiveness against the infection caused by SARS-CoV-2. <b>2021</b> ,	
1036	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <b>2021</b> , 9, 586-594	38
1035	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. <b>2021</b> , 1, 15	1
1034	Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. <b>2021</b> , 21, 986	5
1033	Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients. <b>2022</b> , 94, 161-172	4
1032	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. <b>2021</b> , 6, 71	1
1031	Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis. <b>2021</b> ,	6
1030	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. <b>2021</b> , 95, e0143721	5
1029	A hitchhiker's guide through the COVID-19 galaxy. <b>2021</b> , 232, 108849	0
1028	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <b>2021</b> , 39, 1201-1208	1
1027	Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. <b>2021</b> , 27, 120	2

1026	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. <b>2021</b> , 14,	5
1025	Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. <b>2021</b> , 13, 185-195	0
1024	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial. <b>2021</b> , 174, 1261-1269	33
1023	SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know. <b>2021</b> , 34, 1776-1788	4
1022	Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?. <b>2021</b> , 45, 1690-1702	1
1021	Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report. <b>2021</b> , 1-9	1
1020	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <b>2021</b> , 9, 957-968	26
1019	Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. <b>2021</b> , 16, e0256977	5
1018	Stakes of Knowing the Truth: A Motivational Perspective on the Popularity of a Controversial Scientific Theory. <b>2021</b> , 12, 708751	2
1017	Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. <b>2021</b> , 100, e27228	2
1016	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <b>2021</b> , 11,	6
1015	Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications. <b>2021</b> , 12, 693227	7
1014	Prospective Study of Policies and Use of Therapies for COVID-19 Amongst Australian Health Services during 2020. <b>2021</b> ,	0
1013	Synthetic lethality-based prediction of anti-SARS-CoV-2 targets. <b>2021</b> ,	
1012	Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staffs with a history of allergy.	1
1011	SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing. <b>2021</b> , 21, e2100160	2
1010	A system biology approach identifies candidate drugs to reduce mortality in severely ill COVID-19 patients.	
1009	Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA). <b>2021</b> , e13090	3

1008	Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. <b>2021</b> , 2, 1163-1170.e2	7
1007	COVID-19 en receptores de trasplante renal: ¿qu¿hemos aprendido tras 18 meses de pandemia?. <b>2021</b> , 24, 219-231	
1006	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <b>2021</b> , 12, 752227	5
1005	Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India. <b>2021</b> , 163, 83-90	10
1004	CD38 in the age of COVID-19: a medical perspective. <b>2021</b> , 101, 1457-1486	9
1003	Comparison of the first and second waves of coronavirus disease in Toulouse, France. <b>2021</b> ,	
1002	Scoping insight on antiviral drugs against COVID-19.. <b>2021</b> , 14, 103385	0
1001	COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment - A narrative review. <b>2021</b> , 35, 351-368	16
1000	COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations. <b>2021</b> , 89719002-11048139	5
999	Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. <b>2021</b> , 157, 42-47	1
998	IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. <b>2021</b> , 99, 107998	0
997	Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. <b>2021</b> , 47, 116393	5
996	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <b>2021</b> , 139, 68-79	3
995	Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations. <b>2021</b> , 1246, 131113	6
994	Drug repurposing for COVID-19: Approaches, challenges and promising candidates. <b>2021</b> , 228, 107930	23
993	Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study. <b>2021</b> , 109, 108021	4
992	Novel treatments and trials in COVID-19. <b>2022</b> , 109-120	
991	Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation. <b>2022</b> , 693-718	



990	Lessons learned from COVID-19 therapies: Critical perspectives from the IDSA COVID-19 treatment guideline panel. <b>2021</b> ,	5
989	Mortality after Remdesivir Treatment of Pneumonia in Hospitalised Patients with Laboratory Confirmed COVID-19: National Data in the Italian Real-World Practice Collected by the AIFA Monitoring Register..	
988	Remdesivir - Current evidence & perspective in management of COVID-19 infection. <b>2021</b> , 10, 1808-1813	2
987	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. <b>2021</b> , 11,	
986	Remdesivir for patients with COVID-19. <b>2021</b> , 193, E125	1
985	Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. <b>2021</b> , 3, 100148	4
984	Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. <b>2021</b> , 19, 4684-4701	6
983	Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <b>2021</b> , 62, 799-805	1
982	Clinical Profile and Outcomes of Confirmed COVID 19 at Manila Doctors Hospital. <b>2021</b> , 14, 1-10	
981	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <b>2021</b> , 8, ofab040	10
980	COVID-19 pandemic and the answer of science: a year in review. <b>2021</b> , 93, e20210543	2
979	Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period. <b>2021</b> , 8, 20499361211046669	1
978	Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic. <b>2021</b> , 36, 23-34	15
977	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <b>2021</b> ,	18
976	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. <b>2020</b> , 11, 588106	20
975	Clinical Practice Guideline: Recommendations on Inpatient Treatment of Patients with COVID-19. <b>2021</b> , 118,	18
974	Antiviral treatment of COVID-19: An update. <b>2021</b> ,	16
973	COVID-19 Antiviral and Treatment Candidates: Current Status. <b>2021</b> , 21, e7	5

972	Making sense of contradictory evidence in Covid-19 trials. <b>2021</b> ,	1
971	COVID 19: Have we nailed it?. <b>2021</b> , 38, 377-378	
970	Case Management of COVID-19 (Secondary Version). <b>2021</b> , 4, 191-197	5
969	The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. <b>2021</b> , 12, 20420986211042517	2
968	Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro.	0
967	Using in silico process simulation tools in pharmacy education: Considerations for pivoting to online learning. 124-135	
966	COVID-19 and cancer: A comparative case series. <b>2021</b> , 27, 100339	4
965	High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. <b>2021</b> , 16, e0246396	2
964	Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. <b>2021</b> , 96-102	8
963	Development and application of therapeutic antibodies against COVID-19. <b>2021</b> , 17, 1486-1496	16
962	Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection. <b>2021</b> , 11, 27-31	1
961	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <b>2021</b> , 53, 166-219	11
960	Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. <b>2021</b> , 106, 462-468	5
959	Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL Inhibitors. <b>2021</b> , 13,	20
958	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <b>2021</b> , 10, 507-535	61
957	The journey of antimalarial drugs against SARS-CoV-2: Review article. <b>2021</b> , 24, 100604	17
956	Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. <b>2021</b> , 24, 308-317	38
955	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-Edged Swords. <b>2021</b> ,	0

954	Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. <b>2020</b> , 4, 263-274	3
953	Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value. <b>2021</b> , 5, 129-131	9
952	Genetic mechanisms of critical illness in COVID-19. <b>2021</b> , 591, 92-98	451
951	Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. <b>2020</b> ,	3
950	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials. <b>2020</b> ,	1
949	Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening.	1
948	Cardiac SARS-CoV-2 infection is associated with distinct transcriptomic changes within the heart.	1
947	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2.	5
946	Pandemic trials: evidence-based medicine on steroids. <b>2020</b> , 56,	3
945	Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. <b>2020</b> , 11, 590598	8
944	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. <b>2020</b> , 8, 585832	32
943	A Computational Approach to Explore the Interaction of Semisynthetic Nitrogenous Heterocyclic Compounds with the SARS-CoV-2 Main Protease. <b>2020</b> , 11,	4
942	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <b>2020</b> , 21,	25
941	Fuoidan and Lung Function: Value in Viral Infection. <b>2020</b> , 19,	18
940	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <b>2020</b> , 13,	68
939	COVID-19: general overview, pharmacological options and ventilatory support strategies. <b>2020</b> , 15, 708	2
938	Are homoeopathic drugs being used for the treatment of COVID-19 patients, a kind of repurposing?. <b>2020</b> , 14, 231	2
937	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <b>2020</b> ,	3

936	Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins. <b>2021</b> , 18, 226-240	5
935	Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. <b>2021</b> , 49, 315-354	2
934	Coagulation abnormalities & thromboprophylaxis in COVID-19. <b>2021</b> , 153, 606-618	1
933	Nanotechnology-based approaches in the fight against SARS-CoV-2.. <b>2021</b> , 7, 368-398	2
932	Antiviral therapy and immunotherapy of COVID-19. <b>2021</b> , 34 Suppl 1, 57-59	
931	Liquid repellency enabled antipathogen coatings. <b>2021</b> , 12, 100145	4
930	COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series. <b>2021</b> , 9,	9
929	Programmable nano-reactors for stochastic sensing. <b>2021</b> , 12, 5811	3
928	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. <b>2021</b> ,	1
927	Update Alert 2: Remdesivir for Adults With COVID-19. <b>2021</b> ,	3
926	The use of antiviral drugs in children. <b>2021</b> , 1-14	
925	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. <b>2021</b> ,	2
924	Long Term Immune Response Produced by the SputnikV Vaccine. <b>2021</b> , 22,	2
923	The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants.	1
922	Ondansetron use is associated with lower COVID-19 mortality in a Real-World Data network-based analysis.	
921	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir.	
920	Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic. <b>2021</b> , 33, 580-590	1
919	IFNL4 genetic variant can predispose to COVID-19. <b>2021</b> , 11, 21185	6

918	Antiviral and Immunomodulatory Effects of Root Extract EPs 7630 in SARS-CoV-2-Infected Human Lung Cells. <b>2021</b> , 12, 757666	3
917	Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China. <b>2021</b> ,	1
916	Remdesivir-Associated Significant Bradycardia: A Report of Three Cases.. <b>2021</b> , 16, 79-83	1
915	Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper. <b>2021</b> , 47, 199	2
914	Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19. <b>2021</b> , 11, 20463	0
913	COVID-19 and antimicrobial stewardship: lessons learned, best practices, and future implications. <b>2021</b> , 113, 103-108	6
912	Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China. <b>2021</b> , 10, 100798	1
911	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic.	1
910	Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. <b>2021</b> ,	2
909	COVID-19 and the medicines regulation challenges in times of pandemic. <b>2021</b> , 26, 4693-4702	0
908	Clinical research methodology process: what is changing with COVID-19?. <b>2021</b> , 23, E161-E167	1
907	Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?. <b>2021</b> , 94, 4-5	0
906	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. <b>2021</b> , 10,	1
905	Venovenous extracorporeal membrane oxygenation in patients with COVID-19 respiratory failure. <b>2021</b> ,	2
904	Focusing Treatment on Pregnant Women With COVID Disease. <b>2021</b> , 2, 590945	0
903	Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing. <b>2021</b> , 210, 277-282	6
902	Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce. <b>2021</b> ,	5
901	Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). <b>2021</b> ,	1

8900	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. <b>2021</b> ,	4
899	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <b>2021</b> , 9, 1365-1376	20
898	Extracorporeal Membrane Oxygenation for COVID 2019-Acute Respiratory Distress Syndrome: Comparison between First and Second Waves (Stage 2). <b>2021</b> , 10,	1
897	Dexamethasone in COVID-19: Should we consider a "golden hour" practice?. <b>2021</b> , 75, e14672	
896	Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic. <b>2021</b> , 326, 1801-1802	2
895	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> ,	0
894	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <b>2021</b> , 47, 1258-1270	19
893	COVID-19 Advanced Care. <b>2021</b> , 11,	1
892	Neurotropism of SARS-CoV-2 and neurological diseases of the central nervous system in COVID-19 patients. <b>2021</b> , 1	7
891	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <b>2021</b> ,	7
890	Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects. <b>2021</b> , 13, 1299-1315	0
889	Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study. <b>2021</b> , 16, e0258260	3
888	Efficacy of Interferon- $\gamma$ in Moderate-to-Severe Hospitalised Cases of COVID-19: A Systematic Review and Meta-analysis. <b>2021</b> , 41, 1037-1046	2
887	Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <b>2021</b> , 9, 55	3
886	Mega randomized clinical trials: a definitive solution or a double-edged sword?. <b>2021</b> , 1	
885	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. <b>2021</b> , 9, 100221	4
884	Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France. <b>2021</b> , 52, 35-35	1
883	Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidual stromal cells. <b>2021</b> , 25, 10554-10564	4

882	MOXIDECTIN AND IVERMECTIN INHIBIT SARS-COV-2 REPLICATION IN VERO E6 CELLS BUT NOT IN HUMAN PRIMARY AIRWAY EPITHELIUM CELLS. <b>2021</b> , AAC0154321	7
881	A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. <b>2021</b> , 12, e0254221	2
880	Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China. <b>2021</b> , 14, 7207-7217	0
879	Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. <b>2021</b> , 16, e0258643	5
878	Remdesivir: Quo vadis?. <b>2021</b> , 193, 114800	2
877	Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial. <b>2021</b> , 41, 101152	10
876	Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. <b>2021</b> , 564, 33-38	12
875	Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. <b>2021</b> , 912, 174569	3
874	ROLE OF AYURVEDA AND YOGA FOR COVID-19. <b>2020</b> , 8, 4211-4215	
873	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <b>2021</b> , 1	1
872	El impacto sobre la salud colectiva de las conductas censurables en la investigación sanitaria. <b>2021</b> , 1, 33-41	
871	Immune interventions in COVID-19: a matter of time?. <b>2021</b> ,	2
870	Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets. <b>2021</b> , 17, e10260	4
869	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. <b>2021</b> ,	83
868	SARS-CoV-2-host proteome interactions for antiviral drug discovery. <b>2021</b> , 17, e10396	5
867	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. <b>2021</b> ,	3
866	Characteristics and Outcomes of US Patients Hospitalized With COVID-19. <b>2021</b> , e1-e12	1
865	Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. <b>2021</b> , 2021, 6741290	2

864	Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. <b>2021</b> , 108027	0
863	Seroconversion rate after vaccination against COVID-19 in cancer patients-a systematic review. <b>2021</b> ,	12
862	Establishment of a Rapid Detection System for ISG20-Dependent SARS-CoV-2 Subreplicon RNA Degradation Induced by Interferon- $\beta$ . <b>2021</b> , 22,	0
861	Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. <b>2021</b> ,	14
860	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. <b>2021</b> ,	0
859	Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. <b>2021</b> , 9, 723532	3
858	COVID-19 Treatment at a Glance. <b>2020</b> , 21, 438-445	1
857	From Editor-in-Chief: Concluding year 2020, struck by pandemics, a glimpse of hope to end it, many we need to thank; important news, our performance and few words on subordination. 4,	
856	A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.	
855	Pandemic research for older people: doing it better next time. <b>2021</b> , 50, 276-278	3
854	A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro.	
853	Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding. <b>2022</b> , 7, 1-6	1
852	COVID-19 and antimicrobial resistance: A cross-study. <b>2021</b> , 807, 150873	12
851	Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. <b>2021</b> , 10, 94-111	0
850	Antivirals for Coexistence with COVID-19: Brief Review for General Physicians. <b>2021</b> , 36, e298	1
849	Provision of pharmaceutical services in time of COVID-19 crisis: A libyan vision. <b>2020</b> , 4, 159	
848	COVID-19 Pandemic: The Causative Agent is New, The Problem is Old. <b>2021</b> , 3, 14-19	
847	SARS-Cov-2 Viral Kinetics in Mild COVID-19 Patients Treated with Chloroquine Regimens or Standard of Care. <b>2021</b> , 3, 1-14	



846	Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial.	1
845	Machine Learning and Network Medicine approaches for Drug Repositioning for COVID-19. <b>2021</b> , 100396	3
844	Molecular hydrogen as an adjuvant therapy may be associated with increased oxygen saturation and improved exercise tolerance in a COVID-19 patient. <b>2021</b> , 9, e05039	2
843	An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19. <b>2021</b> , eabl4784	232
842	Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients 3 Months after Hospitalization. <b>2021</b> ,	0
841	Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov. <b>2021</b> , 22, 788	1
840	The Antiviral Activity of Bacterial, Fungal, and Algal Polysaccharides as Bioactive Ingredients: Potential Uses for Enhancing Immune Systems and Preventing Viruses. <b>2021</b> , 8, 772033	9
839	Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. <b>2021</b> , 9,	3
838	Identification and Development of Therapeutics for COVID-19. <b>2021</b> , e0023321	5
837	Governance frameworks for COVID-19 research ethics review and oversight in Latin America: an exploratory study. <b>2021</b> , 22, 147	0
836	Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event.	
835	Prevalence and Clinical Implications of COVID-19 Myocarditis.. <b>2022</b> , 14, 53-62	3
834	Clinical efficacy and safety of interferon- $\beta$ -containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> , 1-7	1
833	Self-medication practices to prevent or manage COVID-19: A systematic review. <b>2021</b> , 16, e0259317	10
832	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. <b>2021</b> , 42, 101188	1
831	Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods.	
830	The interaction of alpha-mangostin and its derivatives against main protease enzyme in COVID-19 using methods. <b>2021</b> , 12, 285-290	
829	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. <b>2021</b> , 8, 679030	

828	New wine in old bottles: Ga-PSMA-11 PET/CT reveals COVID-19 in patients with prostate cancer. <b>2021</b> , 11, 332-336	1
827	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <b>2021</b> , 10,	2
826	DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. <b>2021</b> , 175, 105982	1
825	Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease.. <b>2022</b> , 7, 123-131	0
824	Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System. <b>2021</b> , 12, 689065	2
823	Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. <b>2021</b> , 7,	6
822	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy?. <b>2021</b> ,	23
821	Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial.	2
820	Covid-19: Medical, Social and Psychological Aspects. 2, 1-7	
819	Recommendations on the In-Hospital Treatment of Patients With COVID-19. <b>2021</b> ,	5
818	COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital. <b>2021</b> , 1-6	2
817	Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. <b>2021</b> , 29, 449-467	2
816	Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital.. <b>2021</b> , 13, e19487	0
815	Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents. <b>2021</b> ,	0
814	Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. <b>2021</b> , 14, 8557-8571	9
813	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <b>2021</b> ,	1
812	Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis. <b>2021</b> , 16, e0260544	0
811	Call, chosen, HAT, ANDC: validation of four severity scores in COVID-19 patients. <b>2021</b> , 1	0

810	Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. <b>2021</b> , 1	8
809	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. <b>2021</b> ,	16
808	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <b>2021</b> , 22, 304	0
807	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. <b>2021</b> , 2021, 4078713	1
806	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. <b>2021</b> , 1-6	
805	COVID-19 in Children.. <b>2022</b> , 36, 1-14	1
804	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. <b>2021</b> ,	1
803	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review. <b>2021</b> , 11, 760-768	0
802	Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India.. <b>2021</b> , 13, e19976	0
801	Pulmonary surfactant as a versatile biomaterial to fight COVID-19. <b>2021</b> , 342, 170-170	5
800	Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm.	
799	Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. <b>2021</b> , 1	1
798	Many Trials of Hydroxychloroquine for SARS-CoV-2 Were Redundant and Potentially Unethical: An Analysis of the NIH Clinical Trials Registry. <b>2021</b> ,	0
797	Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. <b>2021</b> , 16, e0257979	1
796	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. <b>2021</b> , 17, 1187-1198	0
795	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. <b>2021</b> , 11, 591	0
794	Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection.. <b>2022</b> , 36, 201-210	8
793	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <b>2021</b> , 12, 761887	6

792	Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study. <b>2021</b> , 11, e053096	0
791	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <b>2021</b> , 27, 7433-7445	7
790	[An interview with Gilles Bloch, CEO of Inserm: Lessons and challenges of an unprecedented crisis]. <b>2021</b> , 37, 959-962	
789	Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. <b>2021</b> ,	1
788	Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. <b>2021</b> , 49, 827	1
787	[Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia]. <b>2021</b> , 37, 1073-1076	
786	SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.. <b>2022</b> , 36, 161-168	3
785	Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). <b>2021</b> ,	4
784	Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach. <b>2021</b> ,	4
783	Treatments for COVID-19: Lessons from 2020 and new therapeutic options.. <b>2021</b> , 62, 43-59	4
782	Computational prediction of the potential target of SARS-CoV-2 inhibitor plitidepsin via molecular docking, dynamic simulations and MM-PBSA calculations. <b>2021</b> ,	1
781	COVID-19 Pandemic Between Severity Facts and Prophylaxis. <b>2021</b> , 16, 1934578X2110412	1
780	Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. <b>2021</b> ,	9
779	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <b>2021</b> , 7, eabj5629	8
778	Directly and Simultaneously Expressing Absolute and Relative Treatment Effects in Medical Data Models and Applications. <b>2021</b> , 23,	2
777	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <b>2021</b> , 16, 1341-1370	9
776	Global lessons learned from COVID-19 mass casualty incidents. <b>2021</b> ,	1
775	Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children. <b>2022</b> , 41, e1-e5	

- 774 Assessing the evidence on remdesivir. **2021**, 21, 1630 1
- 773 Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic.. **2021**, 10, 1
- 772 A Focus on Severe Acute Respiratory Syndrome ( SARS ) Coronavirus ( SARS-CoVs ) 1 and 2. **2022**, 449-485
- 771 Critically ill COVID-19 patients exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 viral burden in the lung. **2021**, 100476 1
- 770 Assessment of proarrhythmic risk for chloroquine and hydroxychloroquine using the CiPA concept. **2021**, 913, 174632 2
- 769 Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. **2021**, 11, 23205 3
- 768 Remdesivir retreatment: another unproven intervention for COVID-19.. **2022**, 0
- 767 Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). **2021**, 8, e706 4
- 766 Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center.. **2021**, 10, 4236-4241 0
- 765 Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. **2021**, 37, e00077721 2
- 764 Anno 2021: Which antivirals for the coming decade?. **2021**, 57, 49-107 3
- 763 Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines.. **2022**, 19, eED6840
- 762 Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19. **2021**, 58, 469580211059734
- 761 Chapter 10:Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses. **2021**, 232-255
- 760 Repurposing Second life for drugs. **2022**, 69, 51-59 0
- 759 [COVID-19 drug candidate pipeline, an overview].. **2022**, 157, 27-30
- 758 Should remdesivir be recommended in France in the early stage of COVID-19.. **2022**,
- 757 Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses.. **2022**, 4

756	The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.. <b>2021</b> , 12, 805535	5
755	Non-significant Trends in COVID-19 Trials: Is There a Significance?. <b>2021</b> ,	1
754	Repurposing of Medicines in the EU: Launch of a Pilot Framework.. <b>2021</b> , 8, 817663	0
753	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. <b>2022</b> , 12, 665	1
752	RdRp inhibitors and COVID-19: Is molnupiravir a good option?. <b>2021</b> , 146, 112517	11
751	HIV and Aging in the Era of ART and COVID-19: Symposium Overview.. <b>2022</b> , 89, S3-S9	
750	Impact of early interferon- $\alpha$ treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.. <b>2021</b> , 146, 112572	1
749	Let's evaluate the pandemic in terms of facts, not impressions. <b>2021</b> , 8, 62-65	
748	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. <b>2021</b> , 10, 1076	2
747	SARS-CoV-2-host cell surface interactions and potential antiviral therapies.. <b>2022</b> , 12, 20200081	0
746	Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact.. <b>2022</b> , 17, e0262462	0
745	Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient.. <b>2022</b> , 1-5	2
744	Human genetic and immunological determinants of critical COVID-19 pneumonia.. <b>2022</b> ,	23
743	A review of COVID-19 therapeutics in pregnancy and lactation. 1753495X2110562	2
742	Low Selectivity Indices of Ivermectin and Macrocyclic Lactones on SARS-CoV-2 Replication In Vitro. <b>2022</b> , 2, 60-75	1
741	The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.. <b>2022</b> , 1-16	2
740	The Goldilocks Time for Remdesivir - Is Any Indication Just Right?. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2 3
739	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.. <b>2022</b> , 15, 5	2

738	Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients.. <b>2022</b> , 11,	0
737	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	
736	Impfstoffentwicklung gegen COVID-19: neue Ziele, neue Technologien. <b>2022</b> , 5, 236-239	
735	COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.. <b>2022</b> , 14, e2022009	1
734	Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.. <b>2022</b> , 1	4
733	Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions.. <b>2022</b> , 208, 247-256	3
732	Non-immune Prophylaxis Against COVID-19 by Targeting Tolerance for Angiotensin II-Triggered SARS-CoV-2 Pathogenesis.. <b>2021</b> , 8, 776903	1
731	Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study.. <b>2022</b> , ,	5
730	Immune-guided therapy of COVID-19.. <b>2022</b> ,	2
729	Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant.	12
728	Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2.. <b>2022</b> , 101658	1
727	Strategies for drug repurposing against coronavirus targets.. <b>2022</b> , 3, 100072	1
726	Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis.	2
725	Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database.. <b>2022</b> , 22, 1	5
724	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy.. <b>2022</b> , 12, e054069	0
723	Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicenter, placebo-controlled trial clinical trial.. <b>2022</b> ,	12
722	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.. <b>2022</b> , 106542	2
721	Pulmonary Aspects of COVID-19.. <b>2022</b> , 73, 81-93	2

720	Potential and Possible Therapeutic Effects of Melatonin on SARS-CoV-2 Infection.. <b>2022</b> , 11,	0
719	Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.. <b>2022</b> , 1	10
718	Serum albumin levels monitoring in ICU in early days and mortality risk association in patients with moderate to severe COVID-19 pneumonia.. <b>2022</b> , 38, 612-616	
717	Consequences of COVID-19 for the Pancreas.. <b>2022</b> , 23,	5
716	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening.. <b>2022</b> , 5, 8-19	0
715	Design and Evaluation of a Novel Peptide-Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease.. <b>2022</b> ,	5
714	Covariant Fitness Clusters Reveal Structural Evolution of SARS-CoV-2 Polymerase Across the Human Population.	0
713	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.. <b>2022</b> , e0323821	1
712	Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors.. <b>2022</b> ,	1
711	Synthesis and biological evaluation of 2-benzylaminoquinazolin-4(3)-one derivatives as a potential treatment for SARS-CoV-2.. <b>2022</b> , 43, 412-416	1
710	Obatoclox inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity .. <b>2022</b> , 1-29	1
709	Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness.	0
708	A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.. <b>2022</b> , 29, 337-349	2
707	Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality.. <b>2022</b> , 11,	
706	Safety profile of COVID-19 drugs in a real clinical setting.. <b>2022</b> , 1	3
705	COVID-19 Drug Development. <b>2021</b> , 32,	3
704	[Antiviral drugs : Potent agents, promising therapies for COVID-19 and therapeutic limitations].. <b>2022</b> , 63, 118	
703	An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.. <b>2021</b> , 55, e11631	1



702	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. <b>2022</b> ,	1
701	Pharmacogenetics of antiviral agents for the treatment of COVID-19. <b>2022</b> , 38-41	1
700	State-of-the-Art Clinical Microbiology in South Korea: Current Trends and Future Prospects.. <b>2022</b> , 10,	
699	'ESCMID COVID-19 living guidelines: drug treatment and clinical management'- Author's reply.. <b>2022</b> ,	0
698	A model of infection and immune response to low dose radiation.. <b>2022</b> , 1-14	1
697	Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud.. <b>2022</b> , 9, ofab645	6
696	Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience.. <b>2022</b> ,	0
695	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.	0
694	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.. <b>2022</b> ,	23
693	A guide to immunotherapy for COVID-19.. <b>2022</b> ,	27
692	Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients.. <b>2022</b> , 100, 569	1
691	Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial.. <b>2022</b> , 43, 101242	5
690	HIV and COVID-19 in Latin America and the Caribbean.. <b>2022</b> , 19, 37	
689	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.. <b>2021</b> , 12, 730127	0
688	Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. <b>2022</b> , 1,	18
687	SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment.	0
686	Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study.. <b>2022</b> ,	2
685	The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.. 7, 24	1

684	Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis.. <b>2021</b> ,		2
683	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	120
682	Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.. <b>2022</b> ,		5
681	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir.. <b>2021</b> , 101529		6
680	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).. <b>2022</b> , 1-6		1
679	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial.. <b>2022</b> ,		
678	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.. <b>2022</b> , 106, 108570		3
677	Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients.. <b>2022</b> , 10,		7
676	COVID-19 in the Immunocompromised Host, including People with HIV. <b>2022</b> ,		1
675	Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.. <b>2022</b> , e0304421		1
674	COVID-19 Vaccine Acceptance and its Predictors among College Students in Addis Ababa, Ethiopia, 2021: A Cross-Sectional Survey.. <b>2022</b> , 16, 255-263		0
673	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan.. <b>2021</b> , 5, 100101		0
672	Global data analysis and risk factors associated with morbidity and mortality of COVID-19.. <b>2022</b> , 26, 101505		6
671	Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results.. <b>2021</b> ,		7
670	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.. <b>2022</b> ,		2
669	Microbiota regulation of viral infections through interferon signaling.. <b>2022</b> ,		6
668	Simultaneous therapeutic targeting of inflammation and virus ameliorates influenza pneumonia and protects from morbidity and mortality.		
667	[Development and progress in respiratory tract infections].. <b>2022</b> , 19, 1-7		

666	Repurposing Ayush-64 for COVID-19: A Computational Study Based on Network Pharmacology and Molecular Docking.. <b>2022</b> ,	0
665	The impact of the COVID-19 pandemic on lifestyle behaviors in children and adolescents: an international overview.. <b>2022</b> , 48, 22	4
664	Therapeutics for COVID-19 and post COVID-19 complications: An update.. <b>2022</b> , 3, 100086	13
663	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.. <b>2022</b> ,	16
662	PHARMACOLOGIC TREATMENT AND MANAGEMENT OF COVID-19. <b>2022</b> ,	
661	Covalent narpaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.. <b>2022</b> ,	0
660	Differential interferon- $\gamma$ subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.. <b>2022</b> , 119,	1
659	Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.. <b>2022</b> , 147, 112700	7
658	Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.. <b>2021</b> , 60, 248-248	4
657	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.. <b>2021</b> , 4, e2141328	8
656	Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: a network meta-analysis of randomised controlled trials. <b>2021</b> ,	3
655	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <b>2021</b> , 23, 28	2
654	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.. <b>2021</b> ,	6
653	Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial.. <b>2021</b> ,	3
652	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <b>2021</b> ,	3
651	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019.. <b>2022</b> , 9, ofab588	1
650	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.. <b>2021</b> , 12, e0334721	7
649	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline.. <b>2021</b> , 30,	3

- 648 Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections.. **2021**, 13, 4
- 647 Pharmacological treatment of COVID-19: an opinion paper. **2021**, 10
- 646 Identification and Development of Therapeutics for COVID-19. **2021**,
- 645 Mucormycosis of the bones of the facial skull, nasal cavity and paranasal sinuses in patients with COVID19. **2021**, 23, 347-358 3
- 644 Chemical Bonding in Homogenous Catalysis Seen Through the Eyes of Vibrational Spectroscopy. **2022**,
- 643 Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club.. **2022**, 74, S244-S250 3
- 642 Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India.. **2022**, 11, 1140-1145
- 641 Current therapeutic choices for coronavirus disease 2019: a state-of-the-art review. **2022**, 79-93
- 640 Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. **2022**, 5-140 3
- 639 [Development of COVID-19 drugs using human iPS cell technology].. **2022**, 157, 124-127
- 638 Identification of Potential Inhibitors Against SARS-CoV-2 3CLpro, PLpro, and RdRP Proteins: An In-Silico Approach. **2022**, 85-112
- 637 Acute management of COVID-19 in the emergency department: An evidence-based review.. **2022**, 11, 424-433 0
- 636 COVID-19 and lung involvement. **2022**, 189-211
- 635 Remdesivir: Mechanism of Metabolic Conversion from Prodrug to Drug.. **2021**, 0
- 634 Nutrition intervention in the management of novel coronavirus pneumonia patients.. **2022**, 17, 243-247
- 633 Stem Cell Therapy and Regenerative Medicine for ARDS: Can Stem Cell Therapy and Regenerative Medicine Contribute to the Protection or Recovery of the Injured Lungs?. **2022**, 159-169
- 632 COVID-19 vaccine hesitancy among health professionals in a tertiary care center at the University of Gondar Specialized Hospital, Ethiopia: A cross-sectional study.. **2022**, 10, 20503121221076991 1
- 631 A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2.

630	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. <b>2022</b> ,	9
629	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. <b>2022</b> , 11,	4
628	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. <b>2022</b> , e13763	1
627	Remdesivir and Human Milk: A Case Study.. <b>2022</b> , 8903344221076539	0
626	Adenosine A2A Receptor (A2AR) agonists improve survival in K28-hACE2 mice following SARS CoV-2 infection.	0
625	Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung.. <b>2022</b> , 18, e1010343	3
624	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.. <b>2022</b> , 27, 13596535221082773	0
623	A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales.. <b>2022</b> ,	1
622	Severe Infections Due to Respiratory Viruses.. <b>2022</b> , 43, 60-74	0
621	Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.. <b>2022</b> , 10, e0256021	0
620	Emerging small molecule antivirals may fit neatly into COVID-19 treatment.. <b>2022</b> , 38, 1-15	1
619	Guidance for the pharmacological management of COVID-19 in the emergency setting.. <b>2022</b> , 1-4	1
618	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.. <b>2022</b> , 14,	3
617	SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.. <b>2022</b> , 18, e1010339	1
616	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.. <b>2022</b> , 7, 57	1
615	An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ 1a and hydroxychloroquine in hospitalized patients with COVID-19 [Final results from the DisCoVeRy trial.	0
614	NF- $\kappa$ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. <b>2022</b> , 11,	0
613	Efficacy of repurposed antiviral drugs: Lessons from COVID-19.. <b>2022</b> ,	2

- 612 Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis.. **2022**, 48, e20210393 3
- 611 Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19.. **2021**, 63, 23-23 0
- 610 Update SARS-CoV-2 Behandlungsempfehlungen ff.die Intensivmedizin. **2022**, 4, 73-82
- 609 Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. **2022**, 60, 21-31 4
- 608 The Interplay between COVID-19 and Cancer: Challenges and Perspectives. **2022**, 43, 019-023
- 607 Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.. **2022**, 17, e0262564 1
- 606 Informed Consent and Protection of Personal Data in Genetic Research on COVID-19.. **2022**, 10, 0
- 605 -Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.. **2022**, 58, 1
- 604 Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.. **2022**, 13, 840639 1
- 603 The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.. **2022**, 2
- 602 Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.. **2022**, 10, 2
- 601 Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.. **2022**, 10, 804404 1
- 600 Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients.. **2022**, 17, e0264301 0
- 599 Low Serum Levels of Interferon Alpha in COVID-19 Patients Are Associated with Older Age.. **2022**, 11, 0
- 598 What's new on the management of obstetric patients who tested positive for Covid-19?. **2022**,
- 597 Efficacy and Safety of a Phytopharmaceutical Drug Derived from *Cocculus hirsutus* in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial.. **2022**, 11, 807 0
- 596 What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. **2022**, 13, 843587 0
- 595 Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial.. **2022**, 9, 819621 0

594	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. <b>2022,</b>	1
593	Coronavirus Usurps the Autophagy-Lysosome Pathway and Induces Membranes Rearrangement for Infection and Pathogenesis.. <b>2022,</b> 13, 846543	0
592	COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?. <b>2022,</b>	0
591	The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges.. <b>2022,</b>	1
590	Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis.. <b>2022,</b>	0
589	Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.. <b>2022,</b> 11,	3
588	Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence.. <b>2022,</b> 1-11	0
587	In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs.. <b>2022,</b> 12, 5320	2
586	Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.. <b>2022,</b> 40, 1761-1767	1
585	Therapeutic strategies for COVID-19 patients: An update.. <b>2022,</b>	
584	?? <b>2022,</b> 125, 243-251	
583	Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.. <b>2022,</b>	0
582	Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations.. <b>2022,</b>	5
581	The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review.. <b>2022,</b>	1
580	Using Explicit Thresholds for Benefits and Harms in partially contextualized GRADE Guidelines. Pilot experience from a living COVID-19 guideline.. <b>2022,</b>	
579	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis.	
578	Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital.. <b>2022,</b> 17, e0264789	2
577	Concerns about subgroup analyses and reason for stopping remdesivir trial.. <b>2022,</b> 194, E389	1

576	Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. <b>2022,</b>	8
575	Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug TreatmentThe Need for Precision Medicine. <b>2022,</b> 4, 216-258	1
574	Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2.. <b>2022,</b> 15,	0
573	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.. <b>2022,</b> 10, 801870	2
572	Homo-harringtonine, highly effective against coronaviruses, is safe in treating COVID-19 by nebulization.. <b>2022,</b> 1	0
571	Can anti-parasitic drugs help control COVID-19?. <b>2022,</b>	1
570	Real World Impact of Remdesivir and Dexamethasone on Clinical Outcomes of Severe Coronavirus Disease 2019 in a Community Hospital.. <b>2022,</b>	1
569	Whole genome sequencing reveals host factors underlying critical Covid-19.. <b>2022,</b>	8
568	Drug dosing in hospitalized obese patients with COVID-19.. <b>2022,</b> 26, 60	0
567	Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells.. <b>2022,</b> 13, 520-523	
566	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.. <b>2022,</b> 23,	0
565	STINGing type I IFN-mediated immunopathology in COVID-19.. <b>2022,</b>	2
564	Use of antibiotics in respiratory viral infections.. <b>2022,</b> 1	
563	Neuroimmunology and Neurological Manifestations of COVID-19.	
562	Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.. <b>2022,</b> 1-7	2
561	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry.. <b>2022,</b> 11,	4
560	Wide-ranging genetic study of severe COVID finds common risk factors.. <b>2022,</b>	
559	SARS-CoV-2 infection and children: Insights from the 6th Workshop on Paediatric Virology (Review). <b>2022,</b> 4,	



558	Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.. <b>2022</b> , 14, 160-168	3
557	Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.. <b>2022</b> ,	1
556	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.. <b>2022</b> , 14,	1
555	Screening Large Population Health Databases for Potential Coronavirus Disease 2019 Therapeutics: A Pharmacoepia-Wide Association Study of Commonly Prescribed Medications.. <b>2022</b> , 9, ofac156	0
554	Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 .. <b>2022</b> , 13, 721103	1
553	Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research. <b>2022</b> , 2, 113-133	1
552	Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.. <b>2022</b> ,	1
551	Factors associated with survival of Iranian patients with COVID-19: comparison of Cox regression and mixture cure model.. <b>2022</b> , 8, 4	2
550	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.. <b>2022</b> , 12, 5207	0
549	[Diagnosis and treatment of COVID-19 in intensive care units].. <b>2022</b> , 117, 177	
548	Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?. <b>2022</b> ,	1
547	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.. <b>2022</b> , 16, 827-841	1
546	Interim Analysis of Impact of Adding Low Dose Pulmonary Radiotherapy to Moderate COVID-19 Pneumonia Patients: IMpaCt-RT Study.. <b>2022</b> , 12, 822902	0
545	Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.. <b>2022</b> ,	7
544	New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts.. <b>2022</b> , 8, 110	2
543	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <b>2022</b> , 16, 951-972	0
542	Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial.	
541	A network biology approach to identify crucial host targets for COVID-19.. <b>2022</b> ,	0

540	Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.. <b>2022</b> , 13, 844749	1
539	Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19.. <b>2022</b> , 10, e00945	1
538	Mono- and combinational drug therapies for global viral pandemic preparedness.. <b>2022</b> , 25, 104112	1
537	Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial.. <b>2022</b> , 13, 690726	1
536	COVID-19 Trials: Who Participates and Who Benefits?. <b>2022</b> , 115, 256-261	0
535	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <b>2022</b> ,	1
534	Identification of novel Ebola virus inhibitors using biologically contained virus.. <b>2022</b> , 200, 105294	0
533	COVID-19 therapeutics: Challenges and directions for the future.. <b>2022</b> , 119, e2119893119	9
532	Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge.. <b>2022</b> , 13, 848676	1
531	ACE2 overexpressing mesenchymal stem cells alleviates COVID-19 lung injury by inhibiting pyroptosis.. <b>2022</b> , 25, 104046	0
530	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.. <b>2022</b> , 12, 5771	0
529	Bioinformatics analysis of potential therapeutic targets for COVID-19 infection in patients with carotid atherosclerosis.. <b>2022</b> , 15, 437-447	
528	Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. <b>2022</b> , 2, e0000231	0
527	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.. <b>2022</b> , 58,	2
526	A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for acute respiratory distress syndrome secondary to COVID-19.. <b>2022</b> ,	1
525	Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan.. <b>2022</b> ,	3
524	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <b>2022</b> , 179, 106201	3
523	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <b>2022</b> ,	0

522	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.. <b>2022</b> , 56, 158-170	2
521	Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.. <b>2022</b> ,	0
520	Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?. <b>2022</b> , 1867, 159140	0
519	Antidepressants for COVID-19: A systematic review.. <b>2022</b> ,	0
518	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.. <b>2022</b> , 202, 105311	0
517	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <b>2022</b> , 11, 100243	0
516	Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. <b>2021</b> , 93, 1306-1315	1
515	The immunologic response to severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 42, 495-505	1
514	An ongoing science-society-ethics experiment: The human challenge trial debate in COVID-19 pandemic.. <b>2021</b> , e54184	
513	The Effects of Vitamin C on the Multiple Pathophysiological Stages of COVID-19.. <b>2021</b> , 11,	0
512	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis.. <b>2021</b> , 5, e12638	10
511	Interim-analysis of the COSA (COVID-19 patients treated with the Seraph <sup>®</sup> 100 Microbind <sup>®</sup> Affinity filter) registry. <b>2021</b> ,	3
510	Identification of novel Ebola virus inhibitors using biologically contained virus.	
509	Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: A single center study.. <b>2022</b> , 38, 405-410	0
508	Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study. <b>2021</b> , 11, 23741	0
507	Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19.. <b>2021</b> ,	3
506	Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. <b>2021</b> , 21, 1218	0
505	Clinical trials during the COVID-19 pandemic: research design and lessons. <b>2021</b> , 214-231	

504	The quandary over Antiviral Therapy for a COVID-19 Patient with Glucose-6-Phosphate Dehydrogenase Deficiency, Hypertension, and Resolved Hepatitis B Infection: A Case Report. <b>2021</b> , 9, 221-224	
503	Clinical features and acute management of COVID-19 in adults. <b>2021</b> , 101-123	1
502	Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019.. <b>2022</b> , 9, ofab581	3
501	Recent insights into COVID-19 in children and clinical recommendations. <b>2021</b> ,	2
500	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <b>2021</b> ,	3
499	COVID-19: management in the ICU. <b>2021</b> , 124-143	1
498	Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.. <b>2021</b> ,	6
497	Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study.. <b>2021</b> ,	3
496	Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules.. <b>2021</b> , 9,	1
495	Determinants of Outcome Among Critically Ill Police Personnel With COVID-19: A Retrospective Observational Study From Andhra Pradesh, India.. <b>2021</b> , 13, e20394	
494	Age-related mortality in 61,993 confirmed COVID-19 cases over three epidemic waves in Aragon, Spain. Implications for vaccination programmes. <b>2021</b> , 16, e0261061	3
493	Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy.	2
492	Finding of the factors affecting the severity of COVID-19 based on mathematical models.. <b>2021</b> , 11, 24224	1
491	Drug discovery to treat COVID-19 two years after its outbreak.. <b>2021</b> , 15, 281-288	2
490	Major Publications in the Critical Care Pharmacotherapy Literature: 2020.. <b>2021</b> , 3, e0590	0
489	Improving oxygen capacity at ITBP Referral Hospital during the second wave of COVID-19 infections in Greater Noida, India An operative targeted intervention.. <b>2021</b> , 1-16	1
488	Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.. <b>2021</b> ,	8
487	Drug repurposing strategies and key challenges for COVID-19 management. <b>2021</b> , 1-17	4

486	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. <b>2021</b> , 14,	2
485	Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study.	
484	TREATMENT COSTS FOR COVID-19 PATIENTS IN A TERTIARY HOSPITAL FROM SERBIA.	0
483	Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.. <b>2021</b> , 12, 747732	2
482	Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. <b>2021</b> , 2,	3
481	Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report. <b>2021</b> , 9, 225-229	
480	Covid-19 in recipients of living donor liver transplantation: A worse or an equivalent outcome?. <b>2021</b> ,	1
479	Proning modus operandi in pregnancies complicated by acute respiratory distress syndrome secondary to COVID-19.. <b>2021</b> , 1-10	1
478	Overview of clinical trials of drugs for the treatment of patients with new coronavirus infection (COVID-19). <b>2021</b> , 21, 177-190	
477	Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen.. <b>2022</b> ,	
476	Drug safety of frequently used drugs and substances for self-medication in COVID-19.. <b>2022</b> , 13, 20420986221094141	
475	Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.. <b>2022</b> , 24, 269	0
474	Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay. <b>2022</b> , 2,	2
473	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs.. <b>2022</b> ,	2
472	A Highly Potent SARS-CoV-2 Blocking Lectin Protein.. <b>2022</b> ,	2
471	Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection.. <b>2022</b> ,	0
470	Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase.. <b>2022</b> ,	1
469	Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection.. <b>2022</b> , 103593	1

- 468 COVID-19 Infection in Children: Diagnosis and Management.. **2022**, 24, 1-12 2
- 467 Caring for the Critically Ill Patient with COVID-19. **2022**,
- 466 Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2.. **2022**, 14, 0
- 465 Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports.. **2022**, 8, 14 1
- 464 The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.. **2022**, 114, 108193 0
- 463 Tracking discussions of complementary, alternative, and integrative medicine in the context of the COVID-19 pandemic: a month-by-month sentiment analysis of Twitter data.. **2022**, 22, 105 0
- 462 Data flow within global clinical trials: a scoping review.. **2022**, 7, 0
- 461 Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).. **2022**, 134, 399
- 460 Interferon Treatments for SARS-CoV-2: Challenges and Opportunities.. **2022**, 1 0
- 459 Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.. **2022**, 109954 0
- 458 Repositioning anticancer drugs as novel COVID-19 antivirals: targeting structural and functional similarities between viral proteins and cancer.. **2022**, 1-23 1
- 457 Management of pneumonia in critically ill patients. **2021**, 375, e065871 3
- 456 An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19.. **2022**, 2022, 9293681
- 455 The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical Trial.. **2021**, 20, 553-559
- 454 Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. **2022**, 33, 487-536
- 453 Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3).. **2022**,
- 452 Coronavirus disease 2019 pandemic two years later—What's next?. **2022**, 63, 1-5
- 451 Pharmacological Management. **2022**, 67-96

450 Low IFN-Response after Cell Stimulation Predicts Hospitalization in COVID-19 Patients.

449 Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.. **2022**, 63, 430-439

2

448 Therapeutics in the Treatment of COVID-19 for Children and Adolescents. **2022**, 29, 1

2

447 Epidemiology and Clinical Characteristics of People with Confirmed SARS-CoV-2 Infection during the Early COVID-19 Pandemic in Saudi Arabia. **2022**, 9, 32

446 Inhibitors of SARS-CoV-2 PLpro.. **2022**, 10, 876212

2

445 Photonics enabled intelligence system to identify SARS-CoV 2 mutations.. **2022**,

1

444 Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.. **2022**,

0

443 Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. **2022**, 2,

0

442 Fatigue Is a Major Symptom at COVID-19 Hospitalization Follow-Up.. **2022**, 11,

0

441 Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks. **2022**, 14, 315-320

1

440 Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).. **2022**,

3

439 Self-Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of the COVID-19 Pandemic: A European Multinational Cross-Sectional Study.. **2022**, 19,

1

438 Covalent narpaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.. **2022**, 13, 2268

10

437 Recombinant Protein Technology in the Challenging Era of Coronaviruses. **2022**, 10, 946

0

436 Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.. **2022**,

0

435 Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial.

1

434 [Viral pneumonia. COVID-19 pneumonia].. **2022**, 13, 3224-3234

433 PF-07321332 (Nirmatrelvir) Does Not Interact with Human ENT1 or ENT2: Implications for COVID-19 Patients.. **2022**,

1

432	Efficacy of Remdesivir in the Intensive Care of Patients with COVID-19-associated Acute Respiratory Distress Syndrome. <b>2022</b> , 151-158	
431	Synthetic lethality-based prediction of anti-SARS-CoV-2 targets.. <b>2022</b> , 104311	1
430	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. <b>2022</b> ,	0
429	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.. <b>2022</b> , 1	1
428	Antiviral Drug Discovery for the Treatment of COVID-19 Infections. <b>2022</b> , 14, 961	3
427	Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany.. <b>2022</b> , 1	0
426	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.. <b>2022</b> , 13, 2576	3
425	[The problem of the use of interferons in the novel coronavirus disease COVID-19 (Coronaviridae: Coronavirinae: Betacoronavirus: Sarbecovirus)].. <b>2022</b> , 67, 115-125	1
424	COVID-19 from emerging global threat to ongoing pandemic crisis. 1-8	0
423	Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.. <b>2022</b> ,	25
422	Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.. <b>2022</b> ,	1
421	Covid-19: Remdesivir has "small effect" against death or progression to ventilation, WHO trial finds.. <b>2022</b> , 377, o1118	1
420	When and which patients should receive remdesivir?. <b>2022</b> ,	
419	Barriers and facilitators to the conduct of critical care research in low and lower-middle income countries: A scoping review.. <b>2022</b> , 17, e0266836	0
418	SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment.. <b>2022</b> , 8, 42	3
417	Cytopathic Effect (CPE )-Based Drug Screening Assay for SARS-CoV-2.. <b>2022</b> , 2452, 379-391	
416	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.. <b>2022</b> ,	0
415	Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study.. <b>2022</b> , 17, e0267283	0



414	Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.. <b>2022</b> , 1-9	0
413	The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants.. <b>2022</b> , eabm7621	3
412	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.. <b>2022</b> ,	0
411	The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.. <b>2022</b> ,	0
410	How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review.. <b>2022</b> ,	
409	Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. <b>2022</b> , 12, 44-52	0
408	Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. <b>2022</b> ,	0
407	ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection.. <b>2022</b> , eabo6294	5
406	Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice.. <b>2022</b> , 18, e1010498	1
405	Ribavirin antiviral combination therapy in COVID 19, a single-center experience.	
404	Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm.	
403	Methylene Blue Is a Nonspecific ProteinProtein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19. <b>2022</b> , 15, 621	0
402	Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. <b>2022</b> , 11, 113-128	3
401	Therapeutic monoclonal antibodies for COVID-19 management: an update.	6
400	Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients.	0
399	Treatment paradigms in Parkinson's Disease and Covid-19. <b>2022</b> ,	
398	COVID-19 management landscape- A need for an affordable to manufacture safe and efficacious bio-therapeutic and prophylactic for developing countries. <b>2022</b> ,	0
397	Remdesivir in the Treatment of COVID-19: A Propensity Score-Matched Analysis from a Public Hospital in New York City Assessing Renal and Hepatic Safety. <b>2022</b> , 11, 3132	1

396	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. <b>2022</b> ,	5
395	COVID-19-Current Therapeutical Approaches and Future Perspectives. <b>2022</b> , 10, 1053	1
394	COVID-19 therapies: do we see substantial progress?. <b>2022</b> , 27,	0
393	Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. <b>2022</b> , 9,	3
392	Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers.	1
391	Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry.	
390	COMPETENCIAS ESENCIALES EN LA FORMACI3N DE RESIDENTES ¿QU3NOS HA ENSE3ADO LA PANDEMIA POR COVID-19?. <b>2022</b> , 100734	
389	Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients.	0
388	Molnupiravir in COVID-19: A scoping review. <b>2022</b> , 14,	0
387	COVID-19 disease in the pulmonology unit of a dedicated COVID-19 hospital Our experience. <b>2022</b> , 70, 18-25	1
386	An Approach to the Treatment of Children With COVID-19. <b>23</b> , Publish Ahead of Print,	1
385	Deep Learning Applied to COVID-19 Detection in X-Ray Images. <b>2022</b> , 202-247	
384	Clinicodemographic profile and predictors of poor outcome in hospitalised COVID-19 patients: a single-centre, retrospective cohort study from India. <b>2022</b> , 12, e056464	0
383	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <b>2022</b> , 8,	2
382	Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.	1
381	Multiple deadlocks in the development of nonprofit drugs. <b>2022</b> ,	
380	Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal. <b>2022</b> , 122, 72-80	0
379	COVID-19 and its impact on cancer, HIV, and mentally ill patients. <b>2022</b> , 95-137	

378	COVID-19 and the Importance of Being Prepared: A Multidisciplinary Strategy for the Discovery of Antivirals to Combat Pandemics. <b>2022</b> , 10, 1342	1
377	The Functional Landscape of SARS-CoV-2 3CL Protease.	1
376	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <b>2022</b> ,	1
375	Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. <b>2022</b> ,	2
374	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. <b>2022</b> , 10, 951	0
373	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <b>2022</b> ,	2
372	No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. 1-10	0
371	Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. <b>2022</b> , 17, e0270196	0
370	Identification and characterization of the anti-SARS-CoV-2 activity of cationic amphiphilic steroidal compounds. <b>2022</b> , 13, 1031-1048	0
369	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. <b>2022</b> , 12,	3
368	SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response..	0
367	Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. <b>2022</b> , 14, 1349	0
366	When virtual screening yields to inactive drugs dealing with false theoretical-friends.	0
365	Impaired serological response to COVID-19 vaccination following anti-cancer therapy: a systematic review and meta-analysis.	3
364	Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2. 13,	
363	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <b>2022</b> , 17, e0269482	1
362	How COVID-19 Affects Lung Transplantation: A Comprehensive Review. <b>2022</b> , 11, 3513	
361	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies.	1

- 360 Host-directed immunotherapy of viral and bacterial infections: past, present and future. 5
- 359 Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. **2022**, 12, e057725 0
- 358 WHO's support for COVID-19 research and knowledge management in the Eastern Mediterranean Region. **2022**, 7, e008737 0
- 357 Defining resistance and tolerance traits in Covid-19: towards a stratified medicine approach.
- 356 Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France. **2022**, 106901
- 355 Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. **2022**, 14, 1247 1
- 354 A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT). **2022**, 12, 856 2
- 353 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. **2022**, 21-63
- 352 Overview of coronavirus pandemic. **2022**, 1-22
- 351 The global impact of pandemics on world economy and public health response. **2022**, 43-48
- 350 Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. Publish Ahead of Print, 0
- 349 Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. **2022**, 14, 1427 0
- 348 Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. **2022**, 14, 1404 1
- 347 The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. **2022**, 5, 0
- 346 Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. **2022**, 10, 1284 1
- 345 Study on Hydroxychloroquine Sulfate Being Given to the Admitted COVID -19 Positive Patients at Institute of JLNMC, Bhagalpur, Bihar, India. **2022**,
- 344 Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents. 0
- 343 How I Treat and Prevent COVID-19 in Patients with Hematologic Malignancies and Recipients of Cellular Therapies. 1

- 342 Characteristics and Outcomes of COVID-19 Survivors Requiring Inpatient Rehabilitation: A Comparison of Two Waves. Publish Ahead of Print, 0
- 341 Emerging Clinical Trial Designs May Accelerate Translation in Hematology: Lessons from COVID-19. 0
- 340 Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. 0
- 339 Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. 1
- 338 Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. **2022**, 101121 0
- 337 Remdesivir in Very Old Patients (80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. **2022**, 11, 3769 1
- 336 Participants' Informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable. **2022**, 0
- 335 Current Effective Therapeutics in Management of COVID-19. **2022**, 11, 3838 3
- 334 Leveraging Real-World Data in COVID-19 Response. 1-33
- 333 COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics. 0
- 332 Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. 3
- 331 Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. **2022**, 23, 7702 1
- 330 Recent Progress in the Development of Opaganib for the Treatment of Covid-19. Volume 16, 2199-2211 0
- 329 Euphorbia neriifolia Leaf Juice on Mild and Moderate COVID-19 Patients: Implications in OMICRON Era. **2022**, 12, 10-18 0
- 328 Vitamin D prescribing practices among clinical practitioners during the COVID-19 pandemic. **2022**, 5, 0
- 327 Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. 13, 0
- 326 Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality. 0
- 325 Optimizing the Design and Analysis of Future AKI Trials. ASN.2021121605 0

- 324 Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
- 323 Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. 174077452211051 o
- 322 Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. **2022**, 11, 269-297 o
- 321 Plasmacytoid Dendritic Cells during COVID-19: ally or adversary?. **2022**, 111148 o
- 320 Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2. **2022**, 18, e1010330 o
- 319 65-Year-Old Man With Weight Loss and Dyspnea on Exertion. **2022**, 97, 1363-1368
- 318 Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone. **2022**, 148, 105814 o
- 317 Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV-2 papain-like protease. **2022**, o
- 316 Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. **2022**, 19, 8845 1
- 315 Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. **2022**, o
- 314 COVID-19 Update: The Golden Time Window for Pharmacological Treatments and Low Dose Radiation Therapy. **2022**, 2, 268-272
- 313 Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. 2201294 o
- 312 Don't Look Up! Your Science Herd Immunity or Herd Mentality?. **2022**, 10, 1463
- 311 Characteristics, treatment and delirium incidence of older adults hospitalized with COVID-19: a multicentre retrospective cohort study. **2022**, 10, E692-E701 o
- 310 Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. **2022**, 58, 1007 o
- 309 A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2. 1-12 o
- 308 Clinical Outcome of Antiviral Therapy on COVID-19 Patients. **2022**, 10, 1058-1061
- 307 Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study. **2022**, 14, 1683 3

- 306 Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants. **2022**, 0
- 305 Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK. 1
- 304 Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19: Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). 13, 1
- 303 The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. 13, 0
- 302 Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report. 0
- 301 Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants. 1
- 300 Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. **2022**, 11, 4464 1
- 299 High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19. 1
- 298 OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients. 0
- 297 Corticosteroids: A Boon or Bane for COVID-19 Patients?. **2022**, 109102 0
- 296 Clinical update of medications associated with QT prolongation among COVID-19 patients. 1-10
- 295 Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation. 3
- 294 Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. **2022**, 14, 3
- 293 Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. 3
- 292 The COVID misinfodemic: not new, never more lethal. **2022**, 1
- 291 Absolute binding free energies of mucroporin and its analog mucroporin-M1 with the heptad repeat 1 domain and RNA-dependent RNA polymerase of SARS-CoV-2. 1-12
- 290 Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study. 0
- 289 A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics. 1

- 288 Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2. 13,
- 287 Characterization of Pathogen Inactivated COVID -19 Convalescent Plasma and Responses in Transfused Patients. o
- 286 Joint inference for competing risks data using multiple endpoints.
- 285 Care of the Seriously Ill Patient with SARS CoV-2. 2022,
- 284 SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. 10,
- 283 PRACTICE OF SELF-MEDICATION AND QUALITY OF LIFE ASSESSMENT AMONG HEALTHCARE WORKERS OF A TERTIARY HOSPITAL IN ASSAM DURING COVID-19 PANDEMIC. 184-189
- 282 Two Years into the COVID-19 Pandemic: Lessons Learned. 4
- 281 A review of clinical efficacy data supporting emergency use authorization for COVID -19 therapeutics and lessons for future pandemics. 1
- 280 Adrenal Gland Function and Dysfunction During COVID-19. 2022, 54, 532-539 o
- 279 Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. 2022, 2022, 1-9 o
- 278 Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies. o
- 277 Immune-related adverse events of biological immunotherapies used in COVID-19. 13, o
- 276 International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship.
- 275 Acceptability and Willingness of UAE Residents to Use OTC Vending Machines to Deliver Self-Testing Kits for COVID-19 and the Implications. Volume 15, 1759-1770 o
- 274 Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19. 1
- 273 Improved efficiency for cross-arm comparisons via platform designs.
- 272 Interferon  $\beta$  spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study. 13, 1
- 271 SARS-CoV-2 immunity and vaccine strategies in people with HIV. o



- 270 Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. **2022**, 29, 2
- 269 COVID-19 Therapeutics: ImproviseAdaptLearn. **2022**, 11, 5312 0
- 268 The scenario of self-medication practices during the covid-19 pandemic; a systematic review. **2022**, 82, 104482 2
- 267 TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. **2022**, 25, 105074 0
- 266 Canakinumab in patients with COVID-19 and type 2 diabetes A multicentre, randomised, double-blind, placebo-controlled trial. **2022**, 53, 101649 1
- 265 Management. **2022**, 167-174 0
- 264 Remdesivir Use and Controversies in COVID-19 Pneumonia: Myths and Reality!. **2022**, 4, 15 0
- 263 Biotechnological Strategies in the Intervention and Treatment of COVID-19. **2022**, 421-442 0
- 262 Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an in silico study. **2022**, 24, 23391-23401 0
- 261 Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity. **2022**, 20, 5181-5192 0
- 260 Pre-hospital Management of COVID-19: Looking for a Future Perspective. **2022**, 395-419 0
- 259 The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study. **2022**, 1 1
- 258 Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2. **2022**, 281-293 0
- 257 Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological Malignancies. 0
- 256 Supplemental Medicines-Nutritions Used by Health Personnel in their own Covid-19 Treatment Schedule. 0
- 255 Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. **2022**, 10, E807-E817 0
- 254 Remdesivir-Induced Pancreatitis in a Patient With Coronavirus Disease 2019. **2022**, 51, e88-e89 0
- 253 Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment. 12, 0

- 252 Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. **2022**, 11, 5066 ○
- 251 The Impact of COVID-19 on Pharmaceutical Shortages and Supply Disruptions for Non-Communicable Diseases Among Public Hospitals of South West, Oromia, Ethiopia. Volume 15, 1933-1943 ○
- 250 COVID-19 in Children and Newborn. **2022**, 305-342 ○
- 249 The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. 9, ○
- 248 Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. **2022**, 92, 430-436 ○
- 247 Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19). 6
- 246 COVID-19: Opportunities to Improve Prognosis. **2022**, 92, 404-411 ○
- 245 Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study. **2022**, 26, 993-999 ○
- 244 A novel logical model of COVID-19 intracellular infection to support therapies development. **2022**, 18, e1010443 ○
- 243 Is It Time to Revisit Remdesivir Use for Severe COVID-19?. **2022**, 26, 983-984 1
- 242 COVID-19 and Kidney Transplantation. **2022**, 21, 238-245 ○
- 241 Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. **2022**, 65, 12044-12054 ○
- 240 A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. **2022**, 100774 2
- 239 COVID-19 Pandemi Sırasında Anti Romatizmal İlaçlara Halkın İlgisi: Tıbbiyedeki Google Trends Analizi, Kesitsel Çalışma. ○
- 238 Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. 13, ○
- 237 COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports. **2022**, 11, 5519 ○
- 236 Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation. ○
- 235 Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19. ○

234	Low baseline IFN- $\gamma$ response could predict hospitalization in COVID-19 patients. 13,	1
233	Race, ethnicity, and health disparities in US children with COVID-19: a review of the evidence and recommendations for the future	1
232	Management of COVID-19: A comprehensive and practical approach. <b>2022</b> ,	0
231	Cardiac Biomarkers and Risk Scores in Relation with History of Atherosclerotic Cardiovascular Disease in Patients Admitted with COVID-19: The Experience of an Eastern European Center. <b>2022</b> , 11, 5671	1
230	Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy. <b>2022</b> , 14, 4720	4
229	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). <b>2022</b> ,	0
228	Traumatic brain injury: progress and challenges in prevention, clinical care, and research. <b>2022</b> ,	5
227	A practical update on the management of patients with COVID-19. <b>2022</b> , 22, 468-474	0
226	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <b>2022</b> , 20,	0
225	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.	0
224	Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. <b>2022</b> , 10, 1553	5
223	A Data Science Approach to Evaluate Drug Effectiveness: Case Study of Remdesivir for Covid-19 Patients in India. <b>2023</b> , 691-712	0
222	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. <b>2022</b> , 7, 163-169	0
221	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. 00236-2022	0
220	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <b>2022</b> , 12, 2143	2
219	Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis. <b>2022</b> , 2022, 1-13	0
218	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <b>2022</b> , 12, 1472	0
217	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. 1-14	2

216	Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study.	0
215	Managing two waves of the COVID-19 pandemic in northern emergency departments in Paris: COVIDORG II. <b>2022</b> , 34, 70-81	0
214	Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia. <b>2022</b> , 2022, 1-10	0
213	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. 1-21	1
212	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. <b>2022</b> , 17, e0273526	0
211	Association of IFNAR2 rs2236757 and OAS3 rs10735079 polymorphisms with susceptibility to COVID-19 infection and severity.	0
210	Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic. <b>2022</b> , 17, e0267815	0
209	Delta variant: Partially sensitive to vaccination, but still worth global attention. <b>2022</b> , 10, 227-235	0
208	Recent advances in small-molecular therapeutics for COVID-19.	0
207	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
206	High dependency renal unit for the management of COVID-19 in patients with severe acute or chronic kidney disease. <b>2022</b> , 101, e30423	0
205	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. <b>2022</b> , 217, 368-378	1
204	Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. <b>2022</b> , 105430	3
203	An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. 1-6	0
202	Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. <b>2022</b> , 1, e000309	1
201	Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study.	1
200	Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.	0
199	Japanese rapid/living recommendations on drug management for COVID -19: updated guidelines (July 2022). <b>2022</b> , 9,	0

198	Dynamic Link Prediction for Discovery of New Impactful COVID-19 Research Approaches. <b>2022</b> , 1-12	0
197	Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia. <b>2022</b> , 10, 1949	1
196	Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. <b>2022</b> , 13,	0
195	Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea. <b>2022</b> , 13, 370-376	0
194	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. 13,	0
193	Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. <b>2022</b> , 101, e30998	0
192	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <b>2022</b> , 12, 1605	2
191	Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revis� de escopo. <b>2022</b> , 46, 1	0
190	A Review of Potential Therapeutic Strategies for COVID-19. <b>2022</b> , 14, 2346	1
189	Dose optimisation and scarce resource allocation: two sides of the same coin. <b>2022</b> , 12, e063436	0
188	Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Volume 16, 3645-3654	1
187	Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report. <b>2022</b> ,	0
186	An introduction to the Marburg virus vaccine consortium, MARVAC. <b>2022</b> , 18, e1010805	2
185	Torsades de Pointes associated with remdesivir treatment for COVID-19 pneumonia.	0
184	COVID-19 and HSCT (Hematopoietic stem cell transplant). <b>2022</b> , 101399	0
183	SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.	1
182	Acute and chronic kidney disease and risk of hospital mortality during COVID-19 pandemic waves in the pre-vaccination era.	0
181	Effect of Remdesivir on moderate to severe COVID-19 patients[utcomes..	0

- 180 Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia. **2022**, 2022, 1-4 0
- 179 Fewer COVID -19 neurological complications with dexamethasone and remdesivir. 0
- 178 COVID-19 and Gut Injury. **2022**, 14, 4409 1
- 177 The efficacy and safety of remdesivir and its combination with other drug for the treatment of COVID-19: a systematic review and meta-analysis. 0
- 176 An Observational Study on Unique High Resolution Computed Tomography Pattern of Post-COVID Pulmonary Fibrosis. 0
- 175 EVALUATION OF OSELTAMIVIR AND FAVIPIRAVIR ON CLINICAL OUTCOMES AND LENGTH OF STAY IN COVID-19 PATIENTS AT FATMAWATI GENERAL HOSPITAL JAKARTA. 84-86 0
- 174 Systematic Down-Selection of Repurposed Drug Candidates for COVID-19. **2022**, 23, 11851 0
- 173 The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. **2022**, 44, 0
- 172 Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13, 1
- 171 Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. **2022**, 0
- 170 Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients. 1
- 169 Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. 0
- 168 Efficient Targeted Delivery of Bifunctional Circular Aptamer ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation. 0
- 167 Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants. 1
- 166 How pragmatic are randomized trials of Remdesivir and Favipiravir for in-hospital treatment of Covid-19: A descriptive methodological review of trial design using the PRECIS-2 framework. **2022**, 0
- 165 Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]). Publish Ahead of Print, 2
- 164 Willingness to Accept COVID-19 Vaccine and Associated Factors Among Adult Household Members in Dire Dawa City Administration, East Ethiopia. Volume 16, 2977-2988 0
- 163 Pharmacological therapies and drug development targeting SARS-CoV-2 infection. **2022**, 0

162	Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: A retrospective multicenter study. <b>2022</b> , 16, 100207	0
161	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <b>2022</b> , 12, 1758	2
160	Safety and Efficacy of Interferon $\beta$ 1b in the Treatment of Severe COVID-19 Patients: An Open-Label Randomized Controlled Trial. <b>2022</b> , 17,	0
159	Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. <b>2022</b> , 77, 102172	0
158	Changes in tactics of COVID-19 drug therapy. <b>2022</b> , 50-57	0
157	V. Current Treatment Approach for COVID-19. <b>2021</b> , 110, 2374-2382	0
156	Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. <b>2022</b> , 36, 2171-2179	1
155	S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie □ AWMF-Registernummer: 021-031 □Stand 15. Juni 2022. <b>2022</b> , 60, 1678-1698	0
154	Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review. <b>2022</b> ,	0
153	Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. <b>2022</b> , 17, e0276751	0
152	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). <b>2022</b> , 11, 6545	0
151	Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. <b>2022</b> ,	0
150	Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?. <b>2022</b> , 10, 2815	0
149	Why Molnupiravir Fails in Hospitalized Patients.	0
148	Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV -2 in the endemic phase?.	1
147	A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future. 1-13	0
146	Effectiveness of Lianhua Qingwen Capsule in Treatment of Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial. <b>2022</b> , 28, 887-894	1
145	The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections.	0

- 144 Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. ○
- 143 A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. 1
- 142 Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. **2022**, ○
- 141 Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. **2022**, 20, 1
- 140 Arzneimittelnutzung unter Pandemiebedingungen. **2022**, 171-187 ○
- 139 Recent advances of nanotechnology in COVID 19: A critical review and future perspective. **2023**, 9, 100118 ○
- 138 Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles. **2023**, 16, 104468 ○
- 137 The Evolving Impact of Myocardial Injury in Patients With COVID-19 Amid the Omicron Wave of the Pandemic. **2023**, 190, 54-60 1
- 136 Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19. **2022**, 12, 34808-34814 1
- 135 Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. **2022**, 17, ○
- 134 COVID-19 pandemic: the impact on Canada's intensive care units. **2022**, 7, 1411-1472 ○
- 133 Expression of Concern: Potential Risks and Unknown Effects of mRNA Vaccines on Population Health (6th Rev). Damages Are Being Materialized. **2022**, 4, 7-43 ○
- 132 Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Publish Ahead of Print, ○
- 131 The evolving landscape of pulmonary arterial hypertension clinical trials. **2022**, 400, 1884-1898 ○
- 130 Honey and Nigella sativa against COVID -19 in Pakistan ( HNS-COVID-PK ): A multicenter placebo-controlled randomized clinical trial. ○
- 129 Lost in Translation: Evaluation of Subcutaneous Interferon- $\gamma$  Treatment for SARS-CoV-2 Infection in Real Life. **2022**, 11, 6952 ○
- 128 Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro. **2022**, 20, ○
- 127 N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. **2022**, 23, 14518 ○



126	Publication ethics during the Covid times: Reflections on research integrity, authorship, peer review and editorial policies. 35, 177-179	0
125	Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A in vitro. DMD-AR-2022-001018	0
124	Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model. 13,	0
123	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. <b>2022</b> , 23, 15027	1
122	Pathological Lung Patterns of COVID-19 and its Clinical Correlation to Disease Severity. <b>2022</b> , 26, 1285-1292	0
121	Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. <b>2022</b> , 13,	1
120	Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. 13,	1
119	Quality, integrity and utility of COVID-19 science: opportunities for public health researchers.	0
118	Severe COVID-19 May Impact Hepatic Fibrosis /Hepatic Stellate Cells Activation as Indicated by a Pathway and Population Genetic Study. <b>2023</b> , 14, 22	0
117	As implicações bióticas da Comissão Parlamentar de Inquérito da Pandemia: o caso Prevent Senior. <b>2022</b> , 11, 52-66	0
116	Lack of efficacy of Interferon $\beta$ 1a in COVID-19 patients with mild to moderate pneumonia. <b>2022</b> ,	0
115	Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.	0
114	Chinese parents' willingness to vaccinate their children against COVID-19: A systematic review and meta-analysis. 10,	0
113	Viral modulation of lipid rafts and their potential as putative antiviral targets.	0
112	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <b>2022</b> , 23,	0
111	Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.	0
110	CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY. <b>2022</b> , 10, 432-445	1
109	Outcomes in Patients with Acute Hypoxemic Respiratory Failure Secondary to COVID-19 Treated with Noninvasive Respiratory Support versus Invasive Mechanical Ventilation.	0

- 108 Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study. 00605-2022 ○
- 107 Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects. **2022**, 12, 2047 ○
- 106 AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. **2022**, ○
- 105 Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients. **2022**, 2, 1758-1767 ○
- 104 Randomized Trials Fit for the 21st Century. **2022**, ○
- 103 Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. 13, ○
- 102 Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. **2022**, 20, ○
- 101 A prospective study of pulmonary outcomes and chest CT the first year after COVID-19. 00575-2022 ○
- 100 Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States. **2022**, 5, e2244505 2
- 99 Mechanical ventilation for COVID-19: Outcomes following discharge from inpatient treatment. **2023**, 18, e0277498 ○
- 98 HIV and COVID-19 Disease. **2023**, 44, 035-049 ○
- 97 A tale of two diseases. ○
- 96 Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial.. ○
- 95 Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2. **2023**, 121253 ○
- 94 A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors. 2
- 93 Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. **2023**, 102189 ○
- 92 Clinical characteristics and clinical outcome of community clusters with SARS-CoV-2 infection. 10, ○
- 91 Comparison of Efficacy and Safety of Low-Dose Versus High-Dose Dexamethasone in Hospitalized COVID-19 Patients: A Meta-Analysis. **2023**, ○

- 90 Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers. ○
- 89 Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score. **2023**, 78, 102188 ○
- 88 Molecular mechanisms and roles of pyroptosis in acute lung injury. **2022**, 135, 2417-2426 ○
- 87 Review of science and technology innovation policies in major Innovative-Oriented countries in response to the COVID-19 pandemic. **2022**, ○
- 86 Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. **2022**, 17, e0278963 ○
- 85 Experience of Using Remdesivir in Patients with Novel Coronavirus Infection. **2022**, 10, 365-380 ○
- 84 Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. **2022**, 21, 1483-1494 ○
- 83 COVID-19 in Pediatrics. **2023**, 255-289 ○
- 82 Sepsis presentation and pathophysiology. **2023**, 489-501 ○
- 81 VDDb: A comprehensive resource and machine learning tool for antiviral drug discovery. **2023**, 2, ○
- 80 Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. Publish Ahead of Print, 1
- 79 Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality. **2023**, 15, 318 ○
- 78 Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. **2023**, 99-139 ○
- 77 Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19. **2023**, 351-368 ○
- 76 Knowledge, attitude and acceptability of COVID-19 vaccine among residents in rural communities in Ghana: a multi-regional study. **2023**, 23, ○
- 75 Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry. **2023**, 19, e1011131 1
- 74 International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship. 12, ○
- 73 Validation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry. ○

- 72 Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized COVID-19 patients: real-world data from resource-limited country. **2023**, 1
- 71 Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. **2023**, 91, 18-25 o
- 70 Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness. **2023**, 20, 2404 o
- 69 Efficient Targeted Delivery of Bifunctional Circular Aptamer-ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation. 2207066 o
- 68 How WHO Solidarity Plus trial participants in countries on four continents are informed in writing. 13, o
- 67 Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19. **2023**, 304-309 o
- 66 Remdesivir for the treatment of COVID-19. **2023**, 2023, o
- 65 Belimumab for the treatment of pediatric patients with lupus nephritis. o
- 64 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, o
- 63 Hydroxychloroquine: Time for Reappraisal of Its Effect in COVID-19 Patients. **2023**, 431-439 o
- 62 Efficacy and Adverse Effects of Remdesivir in Patients with COVID-19 Pneumonia: A Retrospective Study. o
- 61 Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525 o
- 60 Negative Conversion of Polymerase Chain Reaction and Clinical Outcomes according to the SARS-CoV-2 Variant in Critically Ill Patients with COVID-19. **2023**, 86, 142-149 o
- 59 Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether- $\beta$ -cyclodextrin content. o
- 58 The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. **2023**, 213, 105590 o
- 57 Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19. **2023**, 176, 556-560 o
- 56 A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates. **2023**, 326, 199053 o
- 55 Review of the British Thoracic Society Winter Meeting 23 November 2022 23-25 November 2022. **2023**, 78, e1-e1 o

54	Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort. <b>2023</b> , 59, 260	o
53	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <b>2023</b> , 9, e13285	o
52	Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2.	o
51	Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19. <b>2023</b> , 3, 198-217	o
50	An overview on the treatments and prevention against COVID-19. <b>2023</b> , 20,	o
49	Therapeutic options in COVID-19. <b>2023</b> , 647-672	o
48	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study.	o
47	Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID19?. <b>2023</b> , 23,	o
46	Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. <b>2023</b> , 6, e2255815	o
45	Severe influenza infection is associated with inflammatory programmed cell death in infected macrophages. 13,	o
44	Current and Emerging Therapies for COVID-19 in Lung Transplantation.	o
43	Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination. <b>2023</b> , 17, 101-107	o
42	AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2. <b>2023</b> , 63, 1438-1453	1
41	The use of complementary and traditional medicine for the treatment of patients with COVID-19: A systematic review. <b>2023</b> ,	o
40	Remdesivir saves lives. Were 3 years needed to learn that?. <b>2023</b> ,	o
39	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. <b>2023</b> ,	o
38	A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine. <b>2023</b> , 11, 515	o
37	Infecties (COVID-19). <b>2022</b> , 311-323	o

- 36 Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology. **2023**, ○
- 35 Knowledge, Attitude and Practices of Self-Medication Including Antibiotics among Health Care Professionals during the COVID-19 Pandemic in Pakistan: Findings and Implications. **2023**, 12, 481 ○
- 34 Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen. **2023**, 18, 122-135 ○
- 33 Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. **2023**, 117, 109968 ○
- 32 Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex. **2023**, 28, 2294 ○
- 31 A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. **2023**, 11, ○
- 30 Type I interferon signaling induces a delayed antiproliferative response in Calu-3 cells during SARS-CoV-2 infection. ○
- 29 Treating COVID-19: Targeting the Host Response, Not the Virus. **2023**, 13, 712 ○
- 28 Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7. **2023**, 6, 578-586 ○
- 27 The effects of COVID -19 on pediatric and adult solid organ transplant recipients and the emergence of telehealth. ○
- 26 5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". **2022**, 111, 578-584 ○
- 25 Genetic conservation across SARS-CoV-2 non-structural proteins Insights into possible targets for treatment of future viral outbreaks. **2023**, 581, 97-115 ○
- 24 Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. **2023**, 55, 351-360 ○
- 23 Cancer, more than a COVID-19 co-morbidity13, ○
- 22 Chest CT findings and outcomes of COVID-19 in second wave: A cross-sectional study in a tertiary care centre in Northern India. ○
- 21 Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. ○
- 20 Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System. ○
- 19 Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. **2023**, 20, ○

- 18 A combination of vaccination, early multiple-round overall screening, traditional Chinese medicine intervention and treatment window forward can reduce the proportion of severe and critical patients with SARS-CoV-2 B.1.617.2 (Delta) variant infection Experience from the COVID-19 treatment center of Heilongjiang Province. **2023**, 5, ○
- 17 Non-coding RNAs derived from the foot-and-mouth disease virus genome trigger broad antiviral activity against coronaviruses. 14, ○
- 16 Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. **2023**, 18, e0272826 ○
- 15 Remdesivir use and antimicrobial stewardship restrictions during the coronavirus disease 2019 (COVID-19) pandemic in the United States: A cross-sectional survey. **2023**, 3, ○
- 14 Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study. **2023**, ○
- 13 Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 12 Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia. ○
- 11 Therapeutics for COVID-19. **2024**, 282-307 ○
- 10 Immunology of COVID-19. **2024**, 52-71 ○
- 9 COVID-19: Natural History and Spectrum of Disease. **2024**, 72-98 ○
- 8 Treatment options for patients with severe COVID-19. **2023**, ○
- 7 Therapeutic Effectiveness of Interferon-2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. **2023**, 24, 6887 ○
- 6 Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. **2023**, 15, 947 ○
- 5 A Rare Side Effect of COVID-19 Treatment: Avascular Femoral Necrosis. 33-37 ○
- 4 Therapeutic strategies for COVID-19: progress and lessons learned. ○
- 3 Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review. **2023**, 12, ○
- 2 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○
- 1 Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. **2023**, 41, 561-585 ○

